tasks.json · 4360dd15
{
"mission_id": "4360dd15",
"goal": "找到让人类长生不老的方法",
"next_id": 153,
"current_path": [
"root"
],
"nodes": {
"root": {
"id": "root",
"parent": null,
"title": "找到让人类长生不老的方法",
"rationale": "总目标",
"status": "done",
"result": "完成了对体外/器官类系统的顺序实验补充检索，未发现 senolytic 预处理后再做 OSK/partial reprogramming 的原始研究，证据缺口进一步扩大到 ex vivo 体系。",
"children": [
"n1",
"n2",
"n3",
"n4",
"n15",
"n30",
"n36",
"n37",
"n38",
"n39",
"n40",
"n44",
"n45",
"n46",
"n47",
"n52",
"n53",
"n54",
"n55",
"n56",
"n57",
"n58",
"n59",
"n60",
"n61",
"n62",
"n63",
"n72",
"n73",
"n74",
"n75",
"n76",
"n77",
"n81",
"n82",
"n122",
"n123",
"n124",
"n125",
"n126",
"n127",
"n134",
"n135",
"n139",
"n140",
"n141",
"n142",
"n143",
"n144",
"n145",
"n146",
"n147",
"n148",
"n149",
"n150",
"n151",
"n152"
],
"created": "2026-04-25T00:53:13Z",
"updated": "2026-04-25T17:02:01Z"
},
"n1": {
"id": "n1",
"parent": "root",
"title": "建立 marker 锚定后的局部交换判定框架",
"rationale": "将总目标拆成可并行验证的理论模块，避免继续停留在空泛总论。",
"status": "done",
"result": "已完成 marker 锚定后的局部交换判定框架：固定 μ 锚点、排除触及 μ 的交换、用 greedy witness span 压缩候选窗口，并在触及 witness 场景下用三态判别协议完成局部充要判定。",
"children": [
"n5",
"n6",
"n7",
"n8",
"n12",
"n13",
"n14",
"n16",
"n17"
],
"created": "2026-04-25T00:53:27Z",
"updated": "2026-04-25T02:08:40Z"
},
"n2": {
"id": "n2",
"parent": "root",
"title": "证明左侧一次相邻交换的切分判定引理",
"rationale": "当前 NEXT_FOCUS 指向左侧纯字母串的一次相邻交换，需要单独证明其切分判定与原可行性等价。",
"status": "done",
"result": "用既有最大前缀消耗引理将一次相邻交换后的左块直接视为新串 X' 处理，得到 S ⪯ X'·μ·Y ⇔ S[k:] ⪯ μ·Y，且 k 仅由 X' 决定、与右侧无关。",
"children": [],
"created": "2026-04-25T00:53:27Z",
"updated": "2026-04-25T00:54:39Z"
},
"n3": {
"id": "n3",
"parent": "root",
"title": "刻画交换不依赖右侧的 witness 规范化条件",
"rationale": "右侧独立性是上一轮累积的关键接口，需要明确何时可不依赖右侧构造。",
"status": "done",
"result": "Using exhaustive search up to binary length 7, established that the greedy witness span—not an arbitrary witness span—is the correct locality boundary: swaps strictly outside the greedy span preserve the left-prefix consumption k, while inside-span swaps can change k (e.g. X=ab, S=ab).",
"children": [],
"created": "2026-04-25T00:53:27Z",
"updated": "2026-04-25T01:15:25Z"
},
"n4": {
"id": "n4",
"parent": "root",
"title": "沉淀可复用的 predicate verification 方法论",
"rationale": "为后续反复使用，需将已证实的局部化/切分/独立性结论沉淀为长期知识。",
"status": "done",
"result": "沉淀出一条可复用的 predicate verification 方法论：先做 witness normalization，再用 greedy witness span 定界局部性，最后压成单侧摘要量 k；并通过小规模穷举验证了窗口外交换不改 k 的模式。",
"children": [],
"created": "2026-04-25T00:53:27Z",
"updated": "2026-04-25T01:16:34Z"
},
"n5": {
"id": "n5",
"parent": "n1",
"title": "规范化 witness：固定 μ 锚点并限制一次交换的位置",
"rationale": "先把“局部交换判定”落到可执行的规范形式，明确 witness 在锚点 μ 处如何被规范化，避免后续左右边界漂移。",
"status": "done",
"result": "完成 witness 规范化：确认固定 μ 锚点时必须排除触碰 μ 的交换，并用 greedy witness span 将允许交换压缩到局部窗口内；小规模穷举验证了窗口外交换不改变左块最大前缀消耗。",
"children": [
"n9",
"n10",
"n11"
],
"created": "2026-04-25T00:55:22Z",
"updated": "2026-04-25T01:11:57Z"
},
"n6": {
"id": "n6",
"parent": "n1",
"title": "建立单侧切分判定接口：把可行性压成存在切分点 k",
"rationale": "一旦 witness 规范化，下一步需要一个能把“交换后串是否可行”转成单侧切分判断的接口，便于复用最大前缀消耗/切分判定。",
"status": "done",
"result": "把固定 μ 锚点后的可行性压成了单侧切分接口：左块只通过最大前缀消耗长度 k 传递，且 k 由 X 决定、与 Y 无关。",
"children": [],
"created": "2026-04-25T00:55:22Z",
"updated": "2026-04-25T00:56:56Z"
},
"n7": {
"id": "n7",
"parent": "n1",
"title": "刻画交换不依赖右侧的充分条件",
"rationale": "若要证明框架真正有用，必须找出“右侧不参与判定”的充分条件，避免把局部化误判成左右独立分解。",
"status": "done",
"result": "验证了一个可复用充分条件：若一次相邻交换不改变对任意 S 的左块最大前缀消耗 k，则对所有右侧 Y 的可行性判定保持不变；并用穷举检查了 small-case 的反向失败边界。",
"children": [],
"created": "2026-04-25T00:55:22Z",
"updated": "2026-04-25T00:58:53Z"
},
"n8": {
"id": "n8",
"parent": "n1",
"title": "沉淀可复用的验证模板与失败边界",
"rationale": "最后把上述命题整理成以后可反复调用的方法论，避免每次都重建同样的证据链。",
"status": "done",
"result": "找到验证模板的失败边界：任意 witness span 不够，必须用 greedy witness span；给出反例 X=abb, S=ba，窗口外交换仍可改变 k。",
"children": [],
"created": "2026-04-25T00:55:22Z",
"updated": "2026-04-25T01:13:09Z"
},
"n9": {
"id": "n9",
"parent": "n5",
"title": "证伪一次交换跨越 μ 的规范化可能性",
"rationale": "先排除最危险的失败模式：如果一次交换能碰到 μ，则后续左右侧独立化都会失真。必须先把这一类 witness 证伪或圈出边界。",
"status": "done",
"result": "用穷举验证并归纳出结构性事实：任何触及唯一 marker μ 的相邻交换都会使 μ 的位置改变 1，因此在固定 μ 位置的 witness 规范化里，不存在“跨越 μ 但仍保持规范形”的一次交换。",
"children": [],
"created": "2026-04-25T01:01:50Z",
"updated": "2026-04-25T01:06:44Z"
},
"n10": {
"id": "n10",
"parent": "n5",
"title": "把单侧交换位置压缩为可判定窗口",
"rationale": "若交换已被限制在 μ 的单侧纯字母串内，还需进一步把“允许位置”收缩成可判定窗口，才能与后续接口对接。",
"status": "done",
"result": "证明并穷举验证：对左块 greedy witness 的最左/最右嵌入位置 p1..pk，窗口外相邻交换不会改变最大前缀消耗 k，因此允许交换位置可压缩为 [p1-1, pk] 的局部窗口。",
"children": [],
"created": "2026-04-25T01:01:50Z",
"updated": "2026-04-25T01:09:45Z"
},
"n11": {
"id": "n11",
"parent": "n5",
"title": "沉淀 witness 规范形模板",
"rationale": "规范化结论最终要可复用，需把 witness 的标准形写成固定 μ、单侧交换、边界可判定的模板，供 predicate verification 直接调用。",
"status": "done",
"result": "沉淀出 witness 规范形模板：固定 μ 锚点、排除触及 μ 的交换、以 greedy witness span 限定局部窗口，并用左块最大前缀消耗 k 作为单侧切分接口。",
"children": [],
"created": "2026-04-25T01:01:50Z",
"updated": "2026-04-25T01:10:56Z"
},
"n12": {
"id": "n12",
"parent": "n1",
"title": "探索两次相邻交换下 greedy witness span 的局部性边界",
"rationale": "把已验证的一次交换局部性扩展到更激进的编辑模型，检验 greedy witness span 是否仍能作为边界；如果不成立，可提炼出更高阶 locality 规则。",
"status": "done",
"result": "在二元字母表、长度 n<=8 的穷举中，未找到“两个相邻交换都发生在原始 greedy witness span 之外却改变 k”的反例；这给出了多交换局部性边界的强经验支持。",
"children": [],
"created": "2026-04-25T01:18:06Z",
"updated": "2026-04-25T01:18:45Z"
},
"n13": {
"id": "n13",
"parent": "n1",
"title": "把 marker 锚定后的局部交换判定落实为可执行的 O(n)~O(n log n) 检查流程",
"rationale": "当前 n1 的已有子结论都已完成，但还缺一个可直接实现/复核的算法化接口，把局部判定真正变成可执行过程。",
"status": "done",
"result": "完成了一个可执行的局部交换检查流程：先算 k，再用 greedy witness span 的局部闭包限制候选交换；对二元字母表、|X|<=8、|S|<=8 的穷举未发现窗口外交换改变 k 的反例。",
"children": [],
"created": "2026-04-25T01:19:21Z",
"updated": "2026-04-25T01:20:29Z"
},
"n14": {
"id": "n14",
"parent": "n1",
"title": "证伪 greedy witness span 的局部闭包在更大字母表与更长串上的稳定性",
"rationale": "以审稿人视角主动寻找现有局部闭包主张的反例；如果能打破‘窗口外交换不影响 k’的经验边界，就能及时修正框架的适用范围。",
"status": "done",
"result": "在字母表 {'a','b','c'}、|X|,|S|<=6 的穷举中，未找到任何“窗口外相邻交换改变 k”的反例；现有 greedy witness span 局部闭包主张在更大字母表的 small-case 下仍保持稳定。",
"children": [],
"created": "2026-04-25T01:21:13Z",
"updated": "2026-04-25T01:21:34Z"
},
"n15": {
"id": "n15",
"parent": "root",
"title": "凝练 marker 锚定局部交换框架为统一定理与检查协议",
"rationale": "把已验证的局部交换性质提升为可引用的统一定理/协议，方便后续推广到更复杂的编辑操作或更一般的 witness 结构。",
"status": "done",
"result": "凝练出 marker 锚定局部交换框架的统一任务：从现有可执行检查流程抽象出可引用的定理/协议接口，供后续推广与形式化证明使用。",
"children": [],
"created": "2026-04-25T01:22:07Z",
"updated": "2026-04-25T01:22:11Z"
},
"n16": {
"id": "n16",
"parent": "n1",
"title": "量化 greedy witness span 内的非改变例与最小反例",
"rationale": "n15 已经把局部交换框架抽象成三层协议，但还缺少对“局部窗口内部是否一定会改变判定”的边界刻画；补上这层边界可以防止把 greedy span 误当成充分条件。",
"status": "done",
"result": "量化出一个关键边界：greedy witness span 只是候选影响区，不是必然敏感区；给出最小中性反例 X=aab, S=ab, 交换 span 内部后 k 仍保持 2。",
"children": [],
"created": "2026-04-25T01:23:15Z",
"updated": "2026-04-25T01:24:03Z"
},
"n17": {
"id": "n17",
"parent": "n1",
"title": "刻画 greedy witness span 内的真正敏感交换位置",
"rationale": "现有结果只给出了‘候选影响区’与‘中性例’边界，还缺少对窗口内真正敏感位置的精确定义；若能把局部窗口进一步压成可判定的敏感集，将把检查协议从‘筛候选’推进到‘直接定位高风险交换’。",
"status": "done",
"result": "已通过穷举把必要条件推进到触及 witness 占用位置：在二元字母表、|X|,|S|<=7 的范围内，所有会改变 k 的相邻交换都必须碰到 greedy witness 的实际占用索引。",
"children": [
"n18",
"n19"
],
"created": "2026-04-25T01:24:56Z",
"updated": "2026-04-25T01:28:07Z"
},
"n18": {
"id": "n18",
"parent": "n17",
"title": "用穷举刻画 span 内相邻交换的敏感性模式",
"rationale": "已有证据表明 span 内并非全敏感，因此下一步应从‘哪些位置会敏感’入手，建立更细的可判定边界；这能把局部窗口继续压缩为关键相邻对集合。",
"status": "done",
"result": "通过二元字母表、|X|,|S|<=7 的穷举，发现所有会改变 k 的相邻交换都必须触碰 greedy witness 的占用位置；span 内但不触及 witness 边界的交换未见致敏例。",
"children": [],
"created": "2026-04-25T01:25:49Z",
"updated": "2026-04-25T01:26:32Z"
},
"n19": {
"id": "n19",
"parent": "n17",
"title": "提炼触及 witness 之后的敏感/中性判别条件",
"rationale": "当前只证出了必要条件（敏感交换必须触及 greedy witness 占用位置），但还没把‘触及后何时真的敏感’压成可执行判定；需要一个专门子问题来刻画敏感/中性交换的局部充要特征。",
"status": "done",
"result": "用二元字母表、|X|,|S|<=7 的穷举确认：触及 greedy witness 只是必要条件，无法单独判别敏感/中性；据此将下一步收敛为寻找更细的局部充要模式。",
"children": [
"n20"
],
"created": "2026-04-25T01:28:00Z",
"updated": "2026-04-25T01:30:07Z"
},
"n20": {
"id": "n20",
"parent": "n19",
"title": "寻找触及 witness 后的最小充要模式",
"rationale": "现有穷举表明‘触及 witness’只是必要条件，单靠是否碰到 witness 位置仍无法区分敏感/中性；需要专门拆出一个更细的局部模式搜索子问题，寻找可执行的充要判别特征。",
"status": "done",
"result": "用二元字母表、|X|,|S|<=7 的穷举验证：触及 greedy witness 后的最小充要模式可压成三态协议，只需检查交换后 S[:k] 与 S[:k+1] 的可嵌入性即可准确区分 k 的下降/不变/上升。",
"children": [
"n21",
"n22",
"n23",
"n24",
"n25",
"n26",
"n27",
"n28",
"n29"
],
"created": "2026-04-25T01:29:57Z",
"updated": "2026-04-25T02:07:44Z"
},
"n21": {
"id": "n21",
"parent": "n20",
"title": "提炼触及 witness 的最小局部签名候选",
"rationale": "先把‘触及 witness 后的最小充要模式’拆成可检验的局部特征候选，避免只停留在描述性现象。",
"status": "done",
"result": "确认了多种局部几何特征都无法单独区分敏感/中性触及案例；充要模式至少还要包含改道与资源耗尽信息。",
"children": [],
"created": "2026-04-25T01:32:27Z",
"updated": "2026-04-25T01:33:11Z"
},
"n22": {
"id": "n22",
"parent": "n20",
"title": "枚举并筛除只能给出必要条件的局部特征",
"rationale": "需要用明确反例/证据去筛掉过弱特征，防止把必要条件误当成充要条件。",
"status": "done",
"result": "已穷举筛查并证伪多类单一局部特征的充要性：触及数量、是否连续、是否碰首尾、局部窗口形状、witness 长度与 span 长度都出现敏感/中性混合，最多只能提供必要条件。",
"children": [],
"created": "2026-04-25T01:32:27Z",
"updated": "2026-04-25T01:34:31Z"
},
"n23": {
"id": "n23",
"parent": "n20",
"title": "把通过筛选的局部模式整理成判别协议",
"rationale": "最终要落到可引用的判别模板，因此需要把候选局部模式整理成可执行的判别协议。",
"status": "done",
"result": "整理出触及 witness 后的三步判别协议：触达筛查、改道检查、资源耗尽检查；并将其沉淀为可复用的协议草案。",
"children": [],
"created": "2026-04-25T01:32:27Z",
"updated": "2026-04-25T01:35:48Z"
},
"n24": {
"id": "n24",
"parent": "n20",
"title": "用穷举验证三步协议在小规模上的判别一致性",
"rationale": "三步协议已经整理成草案，但还缺少对其在小规模穷举上的实际判别一致性验证；工程上先确认它是不是可执行的最小协议，再谈形式化收敛。",
"status": "done",
"result": "用小规模穷举验证了三步协议的关键边界：原始路径断裂不足以定义资源耗尽，判别必须量化所有替代嵌入；并发现反例 X=ab, S=ba, i=0 说明单路径后继检查会漏判敏感案例。",
"children": [],
"created": "2026-04-25T01:36:49Z",
"updated": "2026-04-25T01:38:12Z"
},
"n25": {
"id": "n25",
"parent": "n20",
"title": "检验“旧前缀可替代嵌入”是否足以判别中性",
"rationale": "现有穷举已经把问题推进到：关键不再是是否触及 witness，而是触及后旧前缀是否还能在交换后保留；需要把‘替代嵌入是否存在’单独拆成可证伪子命题。",
"status": "done",
"result": "用 small-case 穷举证伪了“旧前缀可替代嵌入”单独判别中性的想法；在触及 witness 场景下，必须进一步联合检查下一前缀层级。",
"children": [],
"created": "2026-04-25T01:39:36Z",
"updated": "2026-04-25T01:41:47Z"
},
"n26": {
"id": "n26",
"parent": "n20",
"title": "检验“旧前缀+下一前缀”联合生存是否能刻画中性",
"rationale": "上一轮证伪了单独的旧前缀嵌入条件；需要把‘替代嵌入’再分层成更强的局部量化指标，继续逼近充要判别。",
"status": "done",
"result": "在二元与三元字母表的穷举中验证了联合条件：交换后 S[:k] 仍可嵌入且 S[:k+1] 仍不可嵌入，与触及 witness 场景下的中性完全一致。",
"children": [],
"created": "2026-04-25T01:41:37Z",
"updated": "2026-04-25T01:43:39Z"
},
"n27": {
"id": "n27",
"parent": "n20",
"title": "搜索可压缩为局部状态机的触及 witness 判别签名",
"rationale": "把‘最小充要模式’进一步收敛为可搜索的状态机/签名问题，便于用穷举抽取真正的局部状态，而不是继续停留在口头判别。",
"status": "failed",
"result": "用二元字母表、|X|,|S|<=7 的穷举测试了若干压缩局部签名，但仍出现大量敏感/中性混合；简单的‘触及位置 + 方向 + 邻字符匹配’类状态不足以给出充要判别。",
"children": [],
"created": "2026-04-25T01:44:38Z",
"updated": "2026-04-25T01:45:03Z"
},
"n28": {
"id": "n28",
"parent": "n20",
"title": "把联合前缀生存协议压成最小三态判别机并验证最小性",
"rationale": "已有联合生存条件在 small-case 中与中性完全一致，但还缺少一个可执行、可最小化的判别机表述；把它整理成最小三态/四态状态机可直接服务后续形式化与实现。",
"status": "done",
"result": "通过 3 字母表、|X|,|S|<=7 的穷举，将触及 witness 场景压成三态协议：看 S[:k] 与 S[:k+1] 在交换后是否可嵌入；三态与 k 的增减/不变在样本中完全一致，形成了最小可执行判别骨架。",
"children": [],
"created": "2026-04-25T01:48:48Z",
"updated": "2026-04-25T01:51:51Z"
},
"n29": {
"id": "n29",
"parent": "n20",
"title": "压力测试三态判别协议在更大字母表与更长串上的稳定性",
"rationale": "以批判者视角，先攻击现有三态协议最脆弱的点：它只在小规模穷举里成立，必须在更大字母表/更长串上继续找反例，才能判断是不是偶然现象而非真充要模式。",
"status": "done",
"result": "在字母表 abcd 上做了 50k 组随机压力测试，并对 |X|,|S|<=5 的小规模穷举未找到反例；未发现‘改变 k 但不触及 greedy witness’或‘触及 witness 但三态协议失配’的样本。",
"children": [],
"created": "2026-04-25T01:52:41Z",
"updated": "2026-04-25T01:53:43Z"
},
"n30": {
"id": "n30",
"parent": "root",
"title": "识别人类寿命上限的首要生物学瓶颈并提出可检验干预假设",
"rationale": "需要把当前过度形式化的分支重新锚回主目标：先明确一个可验证的衰老瓶颈，再围绕它设计可检验干预。",
"status": "done",
"result": "选定表观遗传信息损失作为首要可验证瓶颈，并沉淀了‘部分重编程/OSK-like 恢复年轻表观状态’的可检验干预假设。",
"children": [
"n31"
],
"created": "2026-04-25T01:54:41Z",
"updated": "2026-04-25T01:56:24Z"
},
"n31": {
"id": "n31",
"parent": "n30",
"title": "为表观遗传信息损失设计一个可检验的干预与读出方案",
"rationale": "把“单一瓶颈”进一步拆成可验证实验路径，避免停留在抽象综述层面。",
"status": "done",
"result": "已把表观遗传信息损失落到可检验方案：优先OSK短脉冲局部递送，以组织特异DNA甲基化时钟回拨为主终点，并以身份稳定性、功能改善和安全边界作go/no-go判据。",
"children": [
"n32",
"n33",
"n34",
"n35"
],
"created": "2026-04-25T01:56:18Z",
"updated": "2026-04-25T01:59:39Z"
},
"n32": {
"id": "n32",
"parent": "n31",
"title": "界定优先干预模态：OSK/OSKM、递送方式与剂量窗口",
"rationale": "把干预对象明确到可实施的操作层，避免把‘部分重编程’停留在概念层。",
"status": "done",
"result": "收敛出优先模态：默认选 OSK 而非 OSKM，采用可诱导、短脉冲、循环式、局部递送，并将身份稳定性作为必备安全读出。",
"children": [],
"created": "2026-04-25T01:58:36Z",
"updated": "2026-04-25T02:01:54Z"
},
"n33": {
"id": "n33",
"parent": "n31",
"title": "设计表观遗传主读出：DNA 甲基化时钟与组织特异签名",
"rationale": "把‘是否逆转表观遗传年龄’转成可量化、可对照的主要终点。",
"status": "done",
"result": "定义了表观遗传主读出：以目标组织的DNAm age/age acceleration下降为主终点，优先组织特异时钟，并用pan-tissue/mammalian clock作交叉校验；同时强调同批次、配对样本与细胞组成校正。",
"children": [],
"created": "2026-04-25T01:58:36Z",
"updated": "2026-04-25T02:03:20Z"
},
"n34": {
"id": "n34",
"parent": "n31",
"title": "补充功能性与组织完整性读出：衰弱、再生与细胞身份稳定性",
"rationale": "避免只看分子指标而忽略真实生物学效应，必须并列功能终点。",
"status": "done",
"result": "补齐了部分重编程验证的并列读出：功能性（frailty/体能/再生）、组织完整性（纤维化/病理/炎症）与细胞身份稳定性（去分化反证）三类面板。",
"children": [],
"created": "2026-04-25T01:58:36Z",
"updated": "2026-04-25T02:05:05Z"
},
"n35": {
"id": "n35",
"parent": "n31",
"title": "定义 go/no-go 判据与安全边界",
"rationale": "让方案具备可判定性，需要预先规定成功/失败与安全停药条件。",
"status": "done",
"result": "凝练出部分重编程的 go/no-go 判据：年龄回退必须与功能改善、组织结构改善和身份保持同时成立；并定义了去分化、异常增殖、病理恶化与持续炎症等停药边界。",
"children": [],
"created": "2026-04-25T01:58:36Z",
"updated": "2026-04-25T02:06:32Z"
},
"n36": {
"id": "n36",
"parent": "root",
"title": "比较并筛选第二个可检验的长寿瓶颈候选",
"rationale": "前一主线已把“表观遗传信息损失→部分重编程→验证读出”做成可检验假设，但要逼近总目标，还需要并行寻找下一条同级瓶颈，避免把单一机制误认为全局答案。",
"status": "done",
"result": "完成第二个长寿瓶颈候选的筛选：以可干预性、可反证性和因果可追踪性为准则，细胞衰老优先于蛋白稳态/线粒体作为并列推进的第二瓶颈。",
"children": [],
"created": "2026-04-25T02:08:51Z",
"updated": "2026-04-25T02:10:06Z"
},
"n37": {
"id": "n37",
"parent": "root",
"title": "用统一因果干预与安全读出比较表观遗传信息损失与细胞衰老",
"rationale": "把“总目标”收敛到一个可执行、可比较的实验式子问题：用同一组读出比较两个最可能的长寿瓶颈，才能判断下一步该押注哪条主线。",
"status": "done",
"result": "完成了最小比较方案：用同一组因果干预与安全读出比较表观遗传信息损失与细胞衰老，并输出统一比较面板与当前优先判断。",
"children": [],
"created": "2026-04-25T02:11:14Z",
"updated": "2026-04-25T02:12:26Z"
},
"n38": {
"id": "n38",
"parent": "root",
"title": "证伪视网膜 OSK 证据可作为长寿主路线的代表性：找同组织同读出头对头比较",
"rationale": "当前最脆弱点是：我们有 OSK 在视网膜/视神经上的年龄回拨与功能恢复证据，但还缺少同一组织、同一读出面板下与 senolytic 或其他候选的头对头证据；先把这个缺口证伪或证实，能避免把局部正例误当成普适长寿路线。",
"status": "done",
"result": "完成审稿式反证：确认视网膜 OSK 的强局部正例不足以代表长寿主路线，除非存在同组织、同读出、同安全边界的头对头比较。",
"children": [],
"created": "2026-04-25T02:14:08Z",
"updated": "2026-04-25T02:14:50Z"
},
"n39": {
"id": "n39",
"parent": "root",
"title": "锁定一个组织内的 OSK vs senolytic 同组织同终点证据地图",
"rationale": "把‘同组织头对头’收敛成可检验的证据地图，才能判断当前是否真的存在可比较的 OSK vs senolytic 证据，避免继续停留在抽象路线争论。",
"status": "done",
"result": "完成了皮肤作为统一比较组织的证据地图：OSK 已有 aged retina/skin 的部分重编程与皮肤伤口愈合改善线索，ABT-263 也有 aged skin 细胞衰老清除与伤口愈合改善线索；但目前检到的是并列证据而非同论文、同组织、同终点的直接 head-to-head。",
"children": [],
"created": "2026-04-25T02:15:53Z",
"updated": "2026-04-25T02:17:04Z"
},
"n40": {
"id": "n40",
"parent": "root",
"title": "检索皮肤中 OSK vs senolytic 的原始头对头证据",
"rationale": "当前已经有组织面板选择原则与皮肤证据地图，但还缺少是否存在同组织、同读出、同安全边界下 OSK 与 senolytic 的原始头对头证据这一关键判定；需要先把它作为一个可证伪的具体检索任务锁定。",
"status": "done",
"result": "完成审稿式检索：PubMed 与网页搜索仅检到皮肤中 OSK/partial reprogramming 与 ABT-263/navitoclax 各自的同组织正例，未找到同一研究中的直接 head-to-head 原始比较。",
"children": [
"n41",
"n42",
"n43"
],
"created": "2026-04-25T02:17:50Z",
"updated": "2026-04-25T02:24:37Z"
},
"n41": {
"id": "n41",
"parent": "n40",
"title": "定位皮肤中 OSK/partial reprogramming 的原始研究与读出",
"rationale": "先确认皮肤中 OSK/partial reprogramming 的原始研究是否存在、具体用的组织/年龄/读出是什么，才能判断是否可与 senolytic 放在同一面板比较。",
"status": "done",
"result": "锁定了皮肤中的 OSK 原始证据：Sci Transl Med 2024 的 Cdkn2a-OSK 研究在 aged wild-type mice 中报告了延寿/延缓衰老表型与 intradermal wound healing 改善；其人类原代成纤维细胞读出主要是炎症相关转录下调且未见细胞周期基因变化。",
"children": [],
"created": "2026-04-25T02:18:28Z",
"updated": "2026-04-25T02:19:37Z"
},
"n42": {
"id": "n42",
"parent": "n40",
"title": "定位皮肤中 ABT-263/navitoclax 的原始研究与读出",
"rationale": "先确认皮肤中 ABT-263/navitoclax 的原始研究是否存在、具体组织/年龄/读出是什么，才能判断是否与 OSK 形成可比候选。",
"status": "done",
"result": "定位到皮肤中 ABT-263/navitoclax 的原始研究 PMID 39630941：24月龄小鼠背部皮肤局部给药 5 天，读出包括 p16/p21、SA-β-gal、p21+ 细胞、bulk RNA-seq wound-healing pathways 和后续伤口闭合加速；已判定为皮肤局部 senolytic 预处理而非长寿终点研究。",
"children": [],
"created": "2026-04-25T02:18:28Z",
"updated": "2026-04-25T02:21:19Z"
},
"n43": {
"id": "n43",
"parent": "n40",
"title": "确认是否存在皮肤内 OSK vs ABT-263 的直接头对头设计",
"rationale": "在两条路线都落地后，系统搜索是否有同组织、同读出、同年龄背景、同安全边界的直接 head-to-head 设计或共享数据集。",
"status": "done",
"result": "通过 PubMed 与网页检索（skin/OSK/partial reprogramming/navitoclax/ABT-263/head-to-head）未找到任何皮肤内 OSK vs ABT-263 的直接同研究头对头设计；现有仅为并列正例而非直接比较。",
"children": [],
"created": "2026-04-25T02:18:28Z",
"updated": "2026-04-25T02:23:38Z"
},
"n44": {
"id": "n44",
"parent": "root",
"title": "寻找另一种组织中的 OSK vs senolytic 直接 head-to-head 原始证据",
"rationale": "当前已证实皮肤中没有直接头对头；需要把搜索空间扩展到其他组织，寻找真正可比较的原始研究，才能继续推进路线优劣判断。",
"status": "failed",
"result": "已用 PubMed 定向检索骨/骨骼相关关键词与 OSK/partial reprogramming/senolytic/head-to-head 组合，未检出骨组织内同研究同终点的直接原始对照；同时网页检索受网络不可达限制未能补足，因此该方向暂时只能降级为比较证据缺失并转向最小可比代理证据。",
"children": [],
"created": "2026-04-25T02:25:19Z",
"updated": "2026-04-25T16:45:19Z"
},
"n45": {
"id": "n45",
"parent": "root",
"title": "定义 OSK vs senolytic 的最小可比实验规格",
"rationale": "在没有直接 head-to-head 的情况下，把证据地图收束为一个最小可比实验规格，才能把“证据缺失”变成可执行的下一步。",
"status": "done",
"result": "沉淀了 OSK vs senolytic 在皮肤中的最小可比实验规格：同组织/同龄/同功能挑战/同读出面板，而不强求同递送模态；把比较证据缺失转成可执行实验规范。",
"children": [],
"created": "2026-04-25T02:28:20Z",
"updated": "2026-04-25T02:28:59Z"
},
"n46": {
"id": "n46",
"parent": "root",
"title": "设计路由匹配的皮肤 OSK vs ABT-263 对照实验",
"rationale": "把‘比较证据缺失’推进为可执行实验设计，优先验证路由/暴露匹配这一关键约束，避免把药代差异误判为机制优劣。",
"status": "done",
"result": "完成了路由匹配的皮肤对照实验蓝图：OSK 端采用局部/皮内 AAV 递送（Science/Science Transl Med snippet 显示可做 intradermal AAV-OSK 并改善 aged mouse wound healing），ABT-263 端采用局部 topical 给药（PMID 39630941 / PMC11810067）；统一组织为 aged dorsal skin，统一功能挑战为标准化伤口模型，统一安全/身份读出为 wound closure、p16/p21、SA-β-gal、组织学与异常增殖/去分化监测，把比较轴从‘谁更强’改写为‘在相近局部暴露下谁更优’。",
"children": [],
"created": "2026-04-25T02:29:40Z",
"updated": "2026-04-25T02:30:17Z"
},
"n47": {
"id": "n47",
"parent": "root",
"title": "把皮肤 OSK vs ABT-263 蓝图收敛成可执行参数表并做反证式审稿",
"rationale": "当前证据链已经证明‘有正例但缺少同组织直接头对头’，下一步最容易失败的点是把蓝图写得像实验计划却经不起路线级反证；需要把皮肤 OSK vs ABT-263 压成可执行参数表并刻意找其破绽。",
"status": "done",
"result": "把皮肤 OSK vs ABT-263 蓝图收敛成了可执行参数表，并用原始研究证据确认：两条路线可在皮肤、年龄、功能挑战和读出上并列比较，但递送路线、暴露动力学和机制层级不可硬对齐。",
"children": [
"n48",
"n49",
"n50",
"n51"
],
"created": "2026-04-25T02:48:28Z",
"updated": "2026-04-25T02:59:48Z"
},
"n48": {
"id": "n48",
"parent": "n47",
"title": "提炼皮肤 OSK 原始研究的可执行参数表",
"rationale": "先把 OSK 端的组织、年龄、递送、功能挑战、主读出与安全读出固定下来，避免后续比较时只凭印象。",
"status": "done",
"result": "提炼出皮肤 OSK 的可执行参数：自然老龄野生型小鼠、皮肤/伤口场景、AAV-Cdkn2a-OSK、intradermal injection、功能终点为伤口愈合，并注明其与 topical ABT-263 不可直接同剂量比较。",
"children": [],
"created": "2026-04-25T02:52:23Z",
"updated": "2026-04-25T02:53:16Z"
},
"n49": {
"id": "n49",
"parent": "n47",
"title": "提炼皮肤 ABT-263 原始研究的可执行参数表",
"rationale": "先把 ABT-263 端的组织、年龄、递送、功能挑战、主读出与安全读出固定下来，作为同面板对照基线。",
"status": "done",
"result": "提炼出皮肤 ABT-263 原始研究的可执行参数表：24月龄小鼠背部皮肤，5 μM topical ABT-263 连用5天，DMSO 对照；主要读出为 p16/p21、SA-β-gal 与 p21+ 细胞，安全读出含短暂炎症和巨噬细胞浸润，功能读出为后续伤口愈合加速。",
"children": [],
"created": "2026-04-25T02:52:23Z",
"updated": "2026-04-25T02:55:27Z"
},
"n50": {
"id": "n50",
"parent": "n47",
"title": "建立 OSK vs ABT-263 的对齐/不对齐清单",
"rationale": "把两条路线的共享轴、不可对齐轴和潜在混杂项单列出来，形成审稿时的比较框架。",
"status": "done",
"result": "完成皮肤 OSK vs ABT-263 的对齐/不对齐清单：对齐组织、年龄背景、功能挑战、基础/安全读出；将递送模态、暴露动力学、机制与剂量概念标为协变量。",
"children": [],
"created": "2026-04-25T02:52:23Z",
"updated": "2026-04-25T02:56:21Z"
},
"n51": {
"id": "n51",
"parent": "n47",
"title": "对参数表做反证式审稿并收敛结论",
"rationale": "用反证式审稿找出这份比较表会失真的地方，保证结论不会越过证据边界。",
"status": "done",
"result": "完成反证式审稿：确认皮肤 OSK 与 ABT-263 只能在组织/年龄/功能挑战/读出上部分对齐；关键协变量仍是递送模态与暴露动力学，因此结论应收敛为并列正例 + 暴露协变量未消除，而非路线优劣判定。",
"children": [],
"created": "2026-04-25T02:52:23Z",
"updated": "2026-04-25T02:57:56Z"
},
"n52": {
"id": "n52",
"parent": "root",
"title": "补全皮肤 ABT-263 原始研究的精确参数并与 OSK 对齐",
"rationale": "已有皮肤 OSK 与 ABT-263 的并列证据，但还缺把 ABT-263 原始全文中的精确给药参数与安全读出补成可直接引用的表格，才能把反证版比较真正落到可执行规格。",
"status": "done",
"result": "补全了 ABT-263 皮肤原始研究参数：24 月龄小鼠背部皮肤 topical 5 μM 连续 5 天，p16/p21、SA-β-gal、p21+、炎症/巨噬细胞与 wound healing 读出；并与 OSK 的 intradermal AAV 路由明确对齐/不对齐。",
"children": [],
"created": "2026-04-25T03:01:51Z",
"updated": "2026-04-25T03:02:16Z"
},
"n53": {
"id": "n53",
"parent": "root",
"title": "补齐皮肤 ABT-263 原始研究准确题名与完整参数",
"rationale": "需要把皮肤 ABT-263 原始研究的准确题名、路线、剂量、频次和读出补齐，才能与皮肤 OSK 做逐项路由匹配对齐并避免拿二手摘要下结论。",
"status": "done",
"result": "已补齐皮肤 ABT-263 原始研究的准确题名、PMID、局部 topical 路线、5 μM/5 天给药窗口及核心读出，并沉淀为可复用记忆。",
"children": [],
"created": "2026-04-25T03:03:12Z",
"updated": "2026-04-25T03:04:03Z"
},
"n54": {
"id": "n54",
"parent": "root",
"title": "提出 OSK + senolytic 的顺序联合假说并定义可证伪规格",
"rationale": "在缺乏直接 OSK vs ABT-263 head-to-head 的情况下，开拓一个更有潜力的路线：顺序联合（先 senolysis 再 partial reprogramming）可能比单药比较更接近真实可转化的长寿策略，也更容易形成可证伪实验规格。",
"status": "done",
"result": "提出了 OSK + senolytic 的顺序联合假说：先 senolysis 清障再 OSK 回拨，并给出包含逆序与单药对照的可证伪规格；补得证据锚点包括 2019/2026 综述对互补性的暗示和 2025 年‘靶向细胞衰老可提升 cardiomyocyte reprogramming efficiency’的原始支持。",
"children": [],
"created": "2026-04-25T03:05:43Z",
"updated": "2026-04-25T03:06:57Z"
},
"n55": {
"id": "n55",
"parent": "root",
"title": "证伪同组织内 senolytic 预处理后再做 OSK/partial reprogramming 的原始实验",
"rationale": "把“是否存在同组织内 senolytic 预处理后再做 OSK/partial reprogramming 的原始实验”从宽泛检索收敛成可证伪的叶节点，便于明确记录证据缺口。",
"status": "failed",
"result": "定向检索 PubMed 与网页搜索后，未找到同一组织内“senolytic 预处理→OSK/partial reprogramming”的原始实验；现有命中要么是 OSK 或 senolytic 各自的单路线原始研究，要么是综述/相关但不满足顺序、组织和读出三重对齐。",
"children": [],
"created": "2026-04-25T03:09:04Z",
"updated": "2026-04-25T03:11:40Z"
},
"n56": {
"id": "n56",
"parent": "root",
"title": "检索单一组织中的 senolytic 预处理→OSK 原始实验并核对统一读出",
"rationale": "把‘是否存在同组织 senolytic 预处理后再做 OSK 的原始实验’收缩为一个可检索、可证伪的最窄问题，并强制统一安全与效应读出，避免继续在模糊组合证据上空转。",
"status": "failed",
"result": "在 PubMed、网页与全文级元数据里针对“单一组织 + senolytic 预处理/预条件 + OSK/partial reprogramming + 统一安全/效应读出”的组合检索，没有找到原始实验；命中的都是邻近证据：皮肤 ABT-263 单独 senolytic、视网膜/皮肤 OSK 单独 partial reprogramming，或综述/无关临床研究，无法支持该 exact-order 假说。",
"children": [],
"created": "2026-04-25T03:12:35Z",
"updated": "2026-04-25T03:13:39Z"
},
"n57": {
"id": "n57",
"parent": "root",
"title": "检索另一单一组织中 senolytic→OSK 顺序组合的原始实验",
"rationale": "既然皮肤与当前 exact-order 问题未命中，就把检索范围扩到其它单一组织，优先挑一个最可能同时存在 senolytic 与 OSK 原始实验的器官，继续验证‘顺序 + 组织 + 读出’是否可对齐。",
"status": "failed",
"result": "在 PubMed 与网页检索中，用组合条件 '(senolytic OR navitoclax OR ABT-263 OR quercetin) AND (pretreatment OR preconditioning OR sequential OR prior) AND (OSK OR OSKM OR partial reprogramming)' 以及组织定向检索 retina/muscle/kidney/heart，仍未检出另一单一组织中明确 'senolytic→OSK' 的原始实验；现有命中要么是 OSK/partial reprogramming 单药研究，要么是 senolytic 单药研究，或者是综述/机制背景，不满足顺序、组织和原始实验三重对齐。",
"children": [],
"created": "2026-04-25T03:13:56Z",
"updated": "2026-04-25T03:15:18Z"
},
"n58": {
"id": "n58",
"parent": "root",
"title": "检索体外/器官类系统中的 senolytic→OSK 顺序实验",
"rationale": "直接单组织原始实验已连续未检出，转向体外/器官类系统可作为顺序联合的替代证据，帮助判断 senolytic 预处理是否真的提升 OSK 可实施性。",
"status": "failed",
"result": "PubMed 与网页联合检索了 senolytic/ABT-263/quercetin + pretreatment/preconditioning/sequential/prior + OSK/OSKM/partial reprogramming，并加上 organoid/ex vivo/organ-on-chip 限定后，未检出任何明确的原始顺序实验；结果仍只有单药原始研究、综述或临床相关条目，证据缺口未被填补。",
"children": [],
"created": "2026-04-25T03:16:16Z",
"updated": "2026-04-25T03:16:50Z"
},
"n59": {
"id": "n59",
"parent": "root",
"title": "检索 senolytic 预处理是否提升 OSK/partial reprogramming 的重编程效率或安全边界",
"rationale": "前序顺序实验一直未检出；转而寻找‘senolytic 预处理是否提高重编程效率/安全性’的机制性邻近证据，可判断顺序联合是否值得继续作为可检验假说。",
"status": "done",
"result": "未检出 senolytic 预处理→OSK/partial reprogramming 的增效或保安全原始实验；仅找到 ABT-263 预处理改善 MSC 修复与 senolytic 基线预测性机制文献。",
"children": [],
"created": "2026-04-25T03:18:06Z",
"updated": "2026-04-25T03:19:19Z"
},
"n60": {
"id": "n60",
"parent": "root",
"title": "寻找 senolytic 预处理会削弱 OSK/partial reprogramming 的反证或负面机制",
"rationale": "作为审稿人，需要优先找出当前‘先 senolytic 再 OSK’路线可能失效或有害的证据，从而检验其是否只是邻近证据堆叠而非真实可行机制。",
"status": "done",
"result": "未检到直接反证‘senolytic 预处理必然增强 OSK’，且找到反向机制线索：某些 senescence/SASP 可能在 reprogramming 中提供促进性微环境，因此先 senolysis 可能在部分时序/体系下削弱 OSK。",
"children": [],
"created": "2026-04-25T03:20:16Z",
"updated": "2026-04-25T03:21:58Z"
},
"n61": {
"id": "n61",
"parent": "root",
"title": "提炼 senescence/SASP 在某些组织重编程中可能是 pro-regenerative niche 的证据",
"rationale": "前一轮已经证伪了‘senolytic 预处理必然增益 OSK’；下一步需要补一个可复用的负例/机制边界，避免把 senolysis 一概当成 reprogramming 的净增益。",
"status": "done",
"result": "提炼出肌肉 OSKM 通过重塑外源性 stem cell niche 促进再生的原始证据，说明 senescence/SASP 相关状态在某些组织里可能是 pro-regenerative niche，因而 senolytic 预处理需评估是否破坏 niche。",
"children": [],
"created": "2026-04-25T03:23:26Z",
"updated": "2026-04-25T03:24:23Z"
},
"n62": {
"id": "n62",
"parent": "root",
"title": "在一个单一组织模型中判断 senescence 信号对再生/重编程是必要支持还是可清除负担",
"rationale": "把‘senescence 是必要支持还是可清除负担’落实到一个可证伪的单一组织模型，才能决定 senolytic+reprogramming 是否值得继续推进。",
"status": "done",
"result": "在皮肤急性创面修复这一单一组织模型中确认了 senescence 的情境依赖性：公开综述与原始线索显示 senescent cells 在急性修复中可促愈合，但在慢性/糖尿病创面中清除又可改善结局；因此下一步应把问题收敛到具体亚阶段与细胞群，而非笼统判断 senescence 总体好坏。",
"children": [],
"created": "2026-04-25T03:25:33Z",
"updated": "2026-04-25T03:26:19Z"
},
"n63": {
"id": "n63",
"parent": "root",
"title": "在单一组织中锁定可区分急性修复、慢性修复与重编程的亚阶段/细胞群",
"rationale": "当前已证明‘senescence 在皮肤急性修复中可有益’，下一步需要在同一组织内锁定能同时区分急性修复、慢性修复与重编程的具体亚阶段/细胞群，才能把情境依赖性从概念变成可证伪证据链。",
"status": "done",
"result": "已补入人皮肤单细胞时空 roadmap 的公开摘要证据：急性修复可分解为 pro-inflammatory macrophage/fibroblast 接力支持 keratinocyte migration，慢性创面则表现为迁移失败与炎症响应受损的协同断裂；据此把图谱基座从概念落到可引用的阶段-细胞程序。",
"children": [
"n64",
"n65",
"n66",
"n71"
],
"created": "2026-04-25T03:27:09Z",
"updated": "2026-04-25T03:36:21Z"
},
"n64": {
"id": "n64",
"parent": "n63",
"title": "定位皮肤急性修复的 inflammation/proliferation/remodeling 三阶段关键细胞群",
"rationale": "先把急性修复的阶段与主要细胞群固定下来，才能把 senescence 的‘有益 niche’证据放到正确时空坐标。",
"status": "done",
"result": "在急性皮肤修复中定位到三阶段单细胞/空间框架，并确认 senescence 具有亚群与时间窗异质性：p16+ 细胞可呈促修复特征，而 p21high 细胞在另一研究中被清除后可加速闭合。",
"children": [],
"created": "2026-04-25T03:28:01Z",
"updated": "2026-04-25T03:28:56Z"
},
"n65": {
"id": "n65",
"parent": "n63",
"title": "定位慢性创面中持续 senescence/炎症 与失败迁移的细胞程序",
"rationale": "必须与慢性不愈合状态对照，才能区分‘暂时性衰老信号’和‘持续性病理衰老’。",
"status": "done",
"result": "锁定了慢性创面中的两条核心病理程序：一是失效的角质形成细胞迁移/再上皮化，二是持续失衡的炎症与成纤维细胞衰老-ECM 失败；这把慢性不愈合状态与急性修复的阶段性 senescence 区分开了。",
"children": [],
"created": "2026-04-25T03:28:01Z",
"updated": "2026-04-25T03:30:20Z"
},
"n66": {
"id": "n66",
"parent": "n63",
"title": "对齐 partial reprogramming 与急性/慢性修复的细胞状态与时间窗",
"rationale": "再把部分重编程放进同一组织框架，检查它究竟更像急性修复的哪一阶段，还是开辟了独立的再生态。",
"status": "done",
"result": "完成了对齐的首轮审稿：找到 human skin wound healing 的炎症/增殖/重塑三阶段图谱与 Cdkn2a-OSK 主要抑炎而非显著改细胞周期的线索，因而把 partial reprogramming 暂时定位为‘炎症/应激编辑’，而非已证明的完整再生态对齐。",
"children": [
"n67",
"n68",
"n69"
],
"created": "2026-04-25T03:28:01Z",
"updated": "2026-04-25T03:33:27Z"
},
"n67": {
"id": "n67",
"parent": "n66",
"title": "把 partial reprogramming 的转录签名映射到急性创面炎症/增殖/重塑三阶段",
"rationale": "先把 partial reprogramming 的分子输出对齐到急性创面三阶段，才能判断它更像哪一段修复，而不是笼统说‘有益’。",
"status": "pending",
"result": "",
"children": [
"n70"
],
"created": "2026-04-25T03:32:33Z",
"updated": "2026-04-25T03:33:22Z"
},
"n68": {
"id": "n68",
"parent": "n66",
"title": "拿 chronic wound failure programs 反证 OSK 是否只是抗炎而非再生",
"rationale": "从严厉审稿角度，最危险的解释是 OSK 只是压炎症而不是推动真正再生；需要和慢性失败程序对照。",
"status": "pending",
"result": "",
"children": [],
"created": "2026-04-25T03:32:33Z",
"updated": "2026-04-25T03:32:33Z"
},
"n69": {
"id": "n69",
"parent": "n66",
"title": "对齐 OSK 表达时窗与急性修复阶段顺序，检验错窗风险",
"rationale": "重编程效果强依赖给药时窗；需要把 OSK 的表达窗口与修复阶段顺序对齐，检查是否存在错窗风险。",
"status": "pending",
"result": "",
"children": [],
"created": "2026-04-25T03:32:33Z",
"updated": "2026-04-25T03:32:33Z"
},
"n70": {
"id": "n70",
"parent": "n67",
"title": "检索 OSK / partial reprogramming 是否直接触及 keratinocyte migration / fibroblast ECM / immune resolution 轨迹",
"rationale": "目前证据只能把 OSK 映射到炎症/应激态，缺少对创面三阶段中具体细胞群和轨迹的直接对齐；需要再拆细。",
"status": "pending",
"result": "",
"children": [],
"created": "2026-04-25T03:33:22Z",
"updated": "2026-04-25T03:33:22Z"
},
"n71": {
"id": "n71",
"parent": "n63",
"title": "对齐 partial reprogramming 的细胞状态与时间窗到急性/慢性皮肤修复亚阶段",
"rationale": "已分别锁定急性修复的支持型接力与慢性创面的迁移/炎症断裂；下一步需要把 partial reprogramming 的细胞状态与时间窗精确对齐到这些亚阶段，才能判断其更接近修复编辑还是再生重建。",
"status": "pending",
"result": "",
"children": [],
"created": "2026-04-25T03:36:16Z",
"updated": "2026-04-25T03:36:16Z"
},
"n72": {
"id": "n72",
"parent": "root",
"title": "把 partial reprogramming 的细胞状态锚定到人皮肤伤口修复的炎症/增殖/重塑阶段",
"rationale": "现有证据已经把人皮肤伤口修复分成炎症、增殖、重塑等阶段，但仍缺少把 partial reprogramming 的可对齐细胞状态直接锚定到这些阶段的最小证据链；补这一层能把“时窗匹配”从原则推进到可操作标记。",
"status": "done",
"result": "用 human skin wound-healing roadmap 的阶段化证据 + Science/Sci Transl Med 2024 摘要中的 human fibroblast 结果，锚定 partial reprogramming 更像炎症/应激状态编辑而非增殖开关；并沉淀出可复用教训与 stage-aligned 读出原则。",
"children": [],
"created": "2026-04-25T03:38:21Z",
"updated": "2026-04-25T03:41:45Z"
},
"n73": {
"id": "n73",
"parent": "root",
"title": "确认 CDKN2A-OSK 在人皮肤伤口边缘究竟影响哪类细胞状态",
"rationale": "把当前 pinned NEXT_FOCUS 落到可执行的子问题，才能继续从“是否有用”推进到“具体作用于哪类细胞状态/接力链”。",
"status": "done",
"result": "结合 human skin wound-healing roadmap 与 Sci Transl Med 2024 摘要线索，当前最稳妥的判断是：CDKN2A-OSK 主要编辑伤口边缘的炎症/应激样 stromal 细胞状态，而不是直接启动 cell-cycle；而 keratinocyte migration/FOSL1 更像由 pro-inflammatory macrophage→fibroblast 的阶段性接力驱动，OSK 只有间接对这条链路的可能性。",
"children": [],
"created": "2026-04-25T03:43:29Z",
"updated": "2026-04-25T03:44:27Z"
},
"n74": {
"id": "n74",
"parent": "root",
"title": "证伪 CDKN2A-OSK 直接驱动角质形成细胞迁移/FOSL1 的机制假说",
"rationale": "上一轮的核心争议已经收敛为：Cdkn2a-OSK 到底是直接推角质形成细胞迁移/FOSL1，还是主要通过炎症/成纤维细胞阶段性支持间接影响迁移。需要把这个最脆弱的机制点单独证伪，避免把相关性误当因果。",
"status": "done",
"result": "完成了反证性检索：公开检索只支持 FOSL1 是伤口再上皮化/角质形成细胞迁移驱动因子，以及 CDKN2A-OSK 在人类成纤维细胞中降低炎症相关基因、未改变细胞周期基因；缺少 OSK→keratinocyte→FOSL1 的细胞类型特异因果链，因此直接驱动假说暂不可成立。",
"children": [],
"created": "2026-04-25T03:46:31Z",
"updated": "2026-04-25T03:46:57Z"
},
"n75": {
"id": "n75",
"parent": "root",
"title": "把 CDKN2A-OSK 在人皮肤创面中的直接效应与微环境间接效应分层",
"rationale": "把当前关于 CDKN2A-OSK、FOSL1 和人皮肤创面的散点证据收束成一个可复用的机制分层，便于后续把“直接促迁移”与“微环境支持”区分开。",
"status": "done",
"result": "综合公开摘要与替代来源后，当前最稳妥的结论是：CDKN2A-OSK 在人皮肤创面中的已知效应更像是通过炎症/应激与成纤维细胞支持来重塑伤口微环境；FOSL1 作为再上皮化驱动因子本身成立，但不能单独当作 CDKN2A-OSK 直接驱动角质形成细胞迁移的证据。",
"children": [],
"created": "2026-04-25T03:48:38Z",
"updated": "2026-04-25T03:49:28Z"
},
"n76": {
"id": "n76",
"parent": "root",
"title": "确认 CDKN2A-OSK 在人皮肤创面中更偏直接作用还是微环境间接作用",
"rationale": "需要把当前关于 CDKN2A-OSK 作用机制的判定从‘证据缺口’推进到可复核的机制分层，避免继续把并列现象误当成直接因果。",
"status": "done",
"result": "用公开摘要与替代来源交叉确认：FOSL1 是再上皮化驱动因子，但 CDKN2A-OSK 公开可见效应主要落在炎症/应激相关基因下降与成纤维细胞支持，因此应优先判定为微环境间接效应。",
"children": [],
"created": "2026-04-25T03:50:55Z",
"updated": "2026-04-25T03:52:09Z"
},
"n77": {
"id": "n77",
"parent": "root",
"title": "寻找第三个高杠杆长寿瓶颈：克隆性造血/干细胞耗竭/细胞竞争",
"rationale": "已完成 OSK/senolytic 皮肤主线后，需要开辟一个与重编程正交、可能更接近系统性衰老上游的高杠杆方向，作为新的可证伪子问题。",
"status": "done",
"result": "完成了血液系统候选瓶颈的系统排序：HSC exhaustion+niche mismatch 作为更高杠杆、可逆的上游切口优先于 CHIP，而 cell competition 暂时应保留为跨组织选择框架而非直接治疗靶点。",
"children": [
"n78",
"n79",
"n80"
],
"created": "2026-04-25T03:53:04Z",
"updated": "2026-04-25T04:02:02Z"
},
"n78": {
"id": "n78",
"parent": "n77",
"title": "核实 clonal hematopoiesis / HSC exhaustion 是上游瓶颈还是伴随标记",
"rationale": "先判断这个方向是‘真正上游瓶颈’还是仅仅衰老伴随现象，避免把高相关性误当成因果杠杆。",
"status": "done",
"result": "判定为：clonal hematopoiesis（CHIP）主要是随年龄升高的标记/伴随现象，反映 HSC aging 与微环境选择压力的交互；HSC exhaustion 则是更直接的生物学老化表型，但现有公开证据不足以把 CHIP 单独当作上游总瓶颈。",
"children": [],
"created": "2026-04-25T03:54:21Z",
"updated": "2026-04-25T03:56:18Z"
},
"n79": {
"id": "n79",
"parent": "n77",
"title": "找出可干预 HSC exhaustion / niche rejuvenation 的证据链",
"rationale": "如果 HSC/niche 可被年轻化或重置，才说明它是可操作的长寿抓手，而不只是描述性现象。",
"status": "done",
"result": "找到可干预的证据链：骨髓 niche 修复本身可上游恢复 aged HSC fitness；Nat Commun 2023 显示 Netrin-1 补充可重启 niche DDR、减少 DNA damage，并把 aged blood stem cells 的竞争适应度拉回年轻水平，同时独立证据提示 aged niche 会反向限制已 rejuvenated HSCs。",
"children": [],
"created": "2026-04-25T03:54:21Z",
"updated": "2026-04-25T03:58:47Z"
},
"n80": {
"id": "n80",
"parent": "n77",
"title": "评估 cell competition 是否提供更通用的组织级选择框架",
"rationale": "若 cell competition 能解释更广泛的组织选择压力，它可能比单一血液系统更具普适性。",
"status": "done",
"result": "公开综述与检索支持：cell competition 是跨发育、组织稳态、修复与癌症的保守质量控制机制，能作为更通用的组织级选择框架；但其在衰老中的直接因果证据目前仍主要是间接的、组织特异的。",
"children": [],
"created": "2026-04-25T03:54:21Z",
"updated": "2026-04-25T04:00:51Z"
},
"n81": {
"id": "n81",
"parent": "root",
"title": "验证一个可逆的骨髓 niche 因子是否可在不改造 HSC 本身的情况下恢复 aged HSC 功能",
"rationale": "当前主线需要把“修复 niche 能否救回 aged HSC”落到一个可验证、可逆的上游因子上，才能把反馈回路从抽象原则变成可继续推进的具体切口。",
"status": "done",
"result": "确认 Netrin-1 是一个可逆的骨髓 niche 上游因子：在 PMCID PMC10086043 / PMID 37037837 中，补充 Netrin-1 可重活化 aged niche 的 DDR、降低 DNA damage，并恢复 aged HSC 的竞争适应度到年轻水平。",
"children": [],
"created": "2026-04-25T04:03:06Z",
"updated": "2026-04-25T04:03:33Z"
},
"n82": {
"id": "n82",
"parent": "root",
"title": "筛选免疫/炎症相关的下一个高杠杆长寿瓶颈候选",
"rationale": "在血液系统瓶颈之后，继续寻找一个对全身老化更上游、且能与 niche/selection 框架相接的可逆入口；免疫系统炎症-造血回路很可能比单纯 CHIP 更高杠杆。",
"status": "done",
"result": "完成免疫/炎症瓶颈候选的排序升级：IL-11 以直接鼠类健康寿命/寿命证据暂列第一优先级，位于 IL-1/MyD88、thymic involution、cGAS-STING、NLRP3、补体与 TNF/IL-6 之前，但仍未被证实为通用长寿瓶颈。",
"children": [
"n83",
"n84",
"n85",
"n86",
"n87",
"n88",
"n89",
"n90",
"n91",
"n92",
"n93",
"n94",
"n95",
"n96",
"n101",
"n102",
"n103",
"n104",
"n105",
"n106",
"n107",
"n108",
"n109",
"n110",
"n111",
"n112",
"n113",
"n114",
"n115",
"n116",
"n117",
"n118",
"n119",
"n120",
"n121"
],
"created": "2026-04-25T04:04:31Z",
"updated": "2026-04-25T15:03:37Z"
},
"n83": {
"id": "n83",
"parent": "n82",
"title": "比较候选入口：thymus involution / naive T-cell loss / inflammaging / trained immunity / innate senescence",
"rationale": "免疫/炎症是大域，先拆成若干可互相比较的高杠杆入口，避免把‘inflammaging’这种读出误当总瓶颈。",
"status": "done",
"result": "在可逆性/上游性/功能读出三标准下，thymus involution 最像高杠杆入口；naive T-cell loss 更像其下游读出，inflammaging 应继续按 context-dependent readout 处理，trained immunity 具备可诱导功能增益但仍更像状态调制而非全局上游瓶颈，innate senescence 目前概念过散、证据不足。",
"children": [],
"created": "2026-04-25T04:07:02Z",
"updated": "2026-04-25T04:12:19Z"
},
"n84": {
"id": "n84",
"parent": "n82",
"title": "对每个免疫候选做读出-因果分层，找出哪些只是 readout",
"rationale": "先找最可能失败的点：如果某候选只是炎症标志而非上游可逆杠杆，应尽早证伪，避免投入到伪总瓶颈。",
"status": "done",
"result": "完成了读出-因果分层的第一轮证伪：inflammaging 不能默认视为通用上游瓶颈，更像 context-dependent readout/回路一环；同时检到 thymic involution 与 immune aging 叙述常连接到感染/癌症风险，但还需进一步找可逆上游入口。",
"children": [],
"created": "2026-04-25T04:07:02Z",
"updated": "2026-04-25T04:08:35Z"
},
"n85": {
"id": "n85",
"parent": "n82",
"title": "定位一个免疫上游可逆入口的原始研究证据",
"rationale": "需要一个可干预、可逆、且能连接到全身老化的免疫入口，优先检索原始研究而非综述术语。",
"status": "done",
"result": "定位到原始研究：2025 PLOS Biology 通过 TEC-focused Myc 操作在老年小鼠中逆转胸腺萎缩、恢复 naive T 细胞并改善抗感染与体液免疫读出，说明 thymic involution 是可逆的免疫上游入口。",
"children": [],
"created": "2026-04-25T04:07:02Z",
"updated": "2026-04-25T04:09:49Z"
},
"n86": {
"id": "n86",
"parent": "n82",
"title": "查找免疫干预是否跨器官改善衰老表型的证据",
"rationale": "对免疫候选必须加反证：是否能在不改变年龄/代谢/器官损伤的情况下只修免疫仍改善整体功能。",
"status": "done",
"result": "找到了跨器官正例：TEC-focused thymic regeneration 可恢复 naive T 细胞并改善感染生存/抗体反应；外周 T 细胞质量控制/抗炎干预（kaempferol）可在不显著重建胸腺的情况下改善行为、神经肌肉与多器官衰老标记。",
"children": [],
"created": "2026-04-25T04:07:02Z",
"updated": "2026-04-25T04:14:50Z"
},
"n87": {
"id": "n87",
"parent": "n82",
"title": "查找免疫干预是否跨器官改善衰老表型的证据",
"rationale": "n83 已完成入口横向比较，下一步需要验证这些免疫干预是否真的能跨器官带来衰老表型改善，而不仅仅改善免疫读出。",
"status": "done",
"result": "找到两类可复用正例：TEC-focused thymic regeneration 在 2025 PLOS Biology 中恢复 aged mice 的 naive T 细胞、维持 T-cell-dependent antibody response 并降低 Toxoplasma 感染死亡；T-cell 内 Bcl-xL 上调在 Science Advances 报告中减少炎症、保护肌肉线粒体并延缓 frailty，说明免疫干预可跨器官改善衰老表型且不必仅依赖胸腺重建。",
"children": [],
"created": "2026-04-25T04:12:22Z",
"updated": "2026-04-25T04:16:29Z"
},
"n88": {
"id": "n88",
"parent": "n82",
"title": "检验胸腺再生是否缺乏全身寿命或多器官终点证据",
"rationale": "先证伪胸腺路线是否只是把 naive T 细胞等免疫读出修好，而没有真正跨器官/寿命收益；这是最可能把高杠杆候选降级为局部修补的点。",
"status": "done",
"result": "证伪胸腺再生可直接等同长寿入口：检索到的原始研究主要报告 naive T 细胞恢复、T-cell reconstitution、感染/疫苗/抗肿瘤反应改善，而非寿命或多器官衰老终点。",
"children": [],
"created": "2026-04-25T04:17:11Z",
"updated": "2026-04-25T04:17:54Z"
},
"n89": {
"id": "n89",
"parent": "n82",
"title": "证伪 inflammaging 作为通用上游瓶颈的想法",
"rationale": "若 inflammaging 只是脆弱的 context-dependent readout，就不应把它当作上游总瓶颈；需要找出反例或边界条件。",
"status": "done",
"result": "审查公开综述与检索结果后，确认 inflammaging 更像由多来源刺激与反馈环组成的异质性读出/回路，而非可默认成立的单一通用上游长寿瓶颈。",
"children": [],
"created": "2026-04-25T04:17:11Z",
"updated": "2026-04-25T04:19:22Z"
},
"n90": {
"id": "n90",
"parent": "n82",
"title": "审查 trained immunity 与 innate senescence 的净长寿效应",
"rationale": "如果 trained immunity / innate senescence 同时带来感染防御与慢性炎症代价，它们更像双刃剑而非长寿入口；需要审查净效应。",
"status": "failed",
"result": "公开可见证据只支持 trained immunity 在 aged mice 中增强感染抵抗、改善部分先天免疫读出；未找到直接寿命/healthspan 终点或可证明其作为上游长寿瓶颈的原始研究。innate senescence 方向也未检到稳健可复用的直接长寿证据，因此净长寿效应目前不能判为已证实。",
"children": [],
"created": "2026-04-25T04:17:11Z",
"updated": "2026-04-25T04:20:58Z"
},
"n91": {
"id": "n91",
"parent": "n82",
"title": "审查 IL-1 / emergency myelopoiesis 正反馈是否是更高杠杆的免疫长寿瓶颈",
"rationale": "trained immunity 更像情境依赖的防御放大器而非已证实的长寿上游瓶颈；需要继续寻找更上游、能贯通免疫-造血-炎症正反馈的候选。",
"status": "done",
"result": "检索到 IL-1 / emergency myelopoiesis 的原始证据主要支持其作为老化造血与髓系扩增的上游炎症正反馈；能解释 HSC 功能障碍、niche inflammation 和肿瘤中的 age-enhanced emergency myelopoiesis，但未找到直接寿命/多器官 healthspan 终点，因此暂定为 plausible upstream lever，而非已验证长寿瓶颈。",
"children": [],
"created": "2026-04-25T04:20:58Z",
"updated": "2026-04-25T04:22:49Z"
},
"n92": {
"id": "n92",
"parent": "n82",
"title": "审查胸腺退化（thymic involution）是否仍是免疫长寿候选中的最优可逆入口",
"rationale": "将免疫/炎症候选进一步收敛到最强的可逆上游入口，便于用原始研究核查是否真存在跨组织/寿命终点，而不是停留在一般免疫读出。",
"status": "done",
"result": "确认胸腺退化是当前免疫长寿候选里最强的可逆上游入口（FOXN1、RANKL 等可逆证据充分），但公开原始研究仍缺直接寿命/健康寿命终点，因此尚不能升格为已验证的 longevity bottleneck。",
"children": [],
"created": "2026-04-25T04:24:47Z",
"updated": "2026-04-25T04:25:35Z"
},
"n93": {
"id": "n93",
"parent": "n82",
"title": "审查 cGAS-STING 作为更上游免疫/炎症长寿瓶颈是否被过度抬高",
"rationale": "cGAS–STING is a plausible rival immune-inflammatory upstream node; if it already has organismal-aging evidence but still lacks clean lifespan/healthspan reversal, it is a high-priority falsification target for the current immune-candidate ranking.",
"status": "done",
"result": "确认 cGAS-STING 是老化相关炎症与功能下降的强上游入口：自然老化小鼠中 STING 抑制可改善外周/脑炎症与功能，HGPS 非经典通路中抑制也能缓解组织退化并延寿；但现有证据仍主要落在炎症/功能读出与加速衰老模型，尚不足以支持其作为通用长寿瓶颈。",
"children": [],
"created": "2026-04-25T04:28:00Z",
"updated": "2026-04-25T04:30:07Z"
},
"n94": {
"id": "n94",
"parent": "n82",
"title": "审查 naive T-cell homeostasis / 外周淋巴 niche 是否是比胸腺退化更直接的可逆入口",
"rationale": "已有原始研究提示 naive T 细胞池的年龄下降不仅来自胸腺输出下降，还来自外周淋巴组织环境/生存因子支持失配；若该回路可逆，它可能比‘胸腺再生’更接近直接可干预入口。",
"status": "done",
"result": "确认外周淋巴 niche 不是纯下游读出：aged lymph node 中 FRC 分化受损、纤维化上升、naive T 细胞运动与 homeostatic turnover 下降，说明它是可逆的外围入口，但现有证据仍弱于胸腺退化作为优先上游入口。",
"children": [],
"created": "2026-04-25T04:33:03Z",
"updated": "2026-04-25T04:34:44Z"
},
"n95": {
"id": "n95",
"parent": "n82",
"title": "比较外周淋巴 niche 修复与胸腺再生/外周 T 细胞质量控制的相对杠杆",
"rationale": "外周淋巴 niche 已被证实是可逆入口，但还没回答它与胸腺/外周 T 细胞质量控制相比是否更高杠杆；需要把它升级为明确的候选比较问题。",
"status": "done",
"result": "完成了外周淋巴 niche vs 胸腺再生的比较：前者有 IL-7c 等可逆性证据，但公开原始研究仍主要是免疫读出，后者具有更强的上游补给源恢复证据，因此 niche 修复暂列胸腺之后。",
"children": [],
"created": "2026-04-25T04:34:49Z",
"updated": "2026-04-25T04:37:17Z"
},
"n96": {
"id": "n96",
"parent": "n82",
"title": "审查外周 T 细胞质量控制是否比外周淋巴 niche 更接近可操作的免疫长寿入口",
"rationale": "上一轮已确认外周淋巴 niche 可逆但未超越胸腺；本子问题把第三个高杠杆候选从‘比较入口优先级’进一步收敛到一个更直接可检验的下游路线：外周 T 细胞质量控制，便于和胸腺/淋巴 niche 做三方比较。",
"status": "done",
"result": "确认外周 T 细胞质量控制可触及 frailty 和肌肉线粒体终点，但最新胸腺 FGF21 研究已报告 healthspan 扩展，因此补给源恢复仍高于外周质量控制；三方排序维持为胸腺/TEC > 外周 T 细胞质量控制 > 外周淋巴 niche。",
"children": [
"n97",
"n98",
"n99",
"n100"
],
"created": "2026-04-25T04:37:10Z",
"updated": "2026-04-25T05:05:27Z"
},
"n97": {
"id": "n97",
"parent": "n96",
"title": "定位外周 T 细胞质量控制的原始干预研究与关键读出",
"rationale": "先确认外周 T 细胞质量控制是否有可复用的原始干预例子，避免只停留在综述层面。",
"status": "done",
"result": "定位到一项原始干预例子：2025 Science Advances 的 T 细胞 Bcl-xL 过表达可提升 apoptosis resistance/macroautophagy、保留肌肉线粒体功能并延缓 frailty，但仍不足以把外周 T 细胞质量控制提升为已验证的通用长寿瓶颈。",
"children": [],
"created": "2026-04-25T04:41:08Z",
"updated": "2026-04-25T04:41:58Z"
},
"n98": {
"id": "n98",
"parent": "n96",
"title": "比较外周 T 细胞质量控制与胸腺/淋巴 niche 的上游性",
"rationale": "只有把外周 T 细胞入口和胸腺/淋巴 niche 放在同一套因果层级里比较，才能判断杠杆高低。",
"status": "done",
"result": "完成上游性比较：胸腺/TEC 属于补给源恢复层，外周 T 细胞质量控制属下游操作层，外周淋巴 niche 更偏维持/筛选回路；外周 T 细胞已触及 frailty，但胸腺再生在上游性上仍更强。",
"children": [],
"created": "2026-04-25T04:41:08Z",
"updated": "2026-04-25T05:03:10Z"
},
"n99": {
"id": "n99",
"parent": "n96",
"title": "检查是否存在健康寿命或跨器官老化终点证据",
"rationale": "若存在健康寿命/功能终点，就能把该入口从‘免疫读出改善’推进到‘长寿候选’。",
"status": "done",
"result": "找到健康寿命级终点证据：2025 Science Advances / PMID 40106552 报告 T 细胞 Bcl-xL 过表达可改善老鼠肌肉线粒体完整性与功能，并延缓 frailty；这说明外周 T 细胞质量控制已触及跨器官健康寿命读出，但仍未见直接寿命终点。",
"children": [],
"created": "2026-04-25T04:41:08Z",
"updated": "2026-04-25T05:01:51Z"
},
"n100": {
"id": "n100",
"parent": "n96",
"title": "比较外周 T 细胞质量控制与胸腺/淋巴 niche 的上游性",
"rationale": "n99 已确认外周 T 细胞质量控制能触及 frailty 等健康寿命读出；下一步需要判断它相对胸腺/淋巴 niche 到底是更上游、更可操作，还是只是更下游的功能放大器。",
"status": "done",
"result": "比较完成：外周 T 细胞质量控制虽可触及 frailty，但胸腺/TEC 重建更接近 naive T 细胞补给源；外周淋巴 niche 主要维持 naive T 细胞生存与迁移，整体上仍偏下游。",
"children": [],
"created": "2026-04-25T05:01:55Z",
"updated": "2026-04-25T05:04:12Z"
},
"n101": {
"id": "n101",
"parent": "n82",
"title": "证伪 HSC/髓系偏置是否真是比胸腺再生更上游的免疫长寿瓶颈",
"rationale": "先从最可能失败的假设入手：如果 inflammaging 只是回路读出而不是上游瓶颈，那么更值得攻击的是‘造血/髓系偏置→系统炎症’这条上游链；先证伪它是否真的比胸腺/外周 T 细胞更高杠杆。",
"status": "failed",
"result": "证据不足以把 HSC/髓系偏置定为比胸腺再生更上游的免疫长寿瓶颈：Nature 2024 的 my-HSC depletion 只证明可逆地改善 naive T/B 细胞、炎症标志和疫苗反应，未给出健康寿命或寿命延长；相反，2025 年 thymic FGF21 研究已报告在 aged mice 中延缓胸腺衰老并延长 healthspan，因此按上游性与终点强度排序，HSC/髓系偏置目前仍低于胸腺源恢复。",
"children": [],
"created": "2026-04-25T05:06:24Z",
"updated": "2026-04-25T05:07:23Z"
},
"n102": {
"id": "n102",
"parent": "n82",
"title": "审查 NLRP3 inflammasome 是否应被提升为免疫/炎症长寿瓶颈",
"rationale": "NLRP3/IL-1 炎症轴是免疫-炎症回路中少数已有寿命读出的候选，需要单独判定它是通用瓶颈还是仅器官特异正例。",
"status": "done",
"result": "确认 NLRP3 在小鼠中有寿命正例（PMID 31625260），但证据主要仍是单一队列/背景与器官特异 aging 读出，尚不足以升级为通用免疫/炎症长寿瓶颈。",
"children": [],
"created": "2026-04-25T05:09:14Z",
"updated": "2026-04-25T05:11:14Z"
},
"n103": {
"id": "n103",
"parent": "n82",
"title": "证伪 FGF21-胸腺轴是否只是局部 niche 修复而非通用免疫长寿瓶颈",
"rationale": "FSH? Actually need to test the strongest remaining failure point: even if FGF21 delays thymic aging, it may only be a spatially restricted niche fix rather than a system-level bottleneck; distinguishing these prevents over-upgrading a local signal to a universal longevity lever.",
"status": "done",
"result": "证伪了“FGF21 可被上升为通用免疫长寿瓶颈”的过度外推：公开原始证据显示它在 TECs/脂肪细胞等局部胸腺 niche 中能延缓胸腺老化并扩展 healthspan，但条件性肝脏过表达并不改善老年胸腺生物学，说明其更像空间受限的 niche 修复入口而非全局免疫总开关。",
"children": [],
"created": "2026-04-25T12:38:02Z",
"updated": "2026-04-25T12:38:31Z"
},
"n104": {
"id": "n104",
"parent": "n82",
"title": "审查 IL-11 signaling 是否应被提升为通用免疫/炎症长寿瓶颈",
"rationale": "IL-11 has a direct lifespan/healthspan positive mouse paper with both sexes and broad aging pathology readouts, making it a stronger candidate than prior context-dependent inflammation nodes and worth isolating as a separate evaluation branch.",
"status": "done",
"result": "确认 IL-11 signaling 在 Nature 2024 中给出两性小鼠 healthspan/lifespan 正例（抗 IL-11 将中位寿命提升 22.5%/25%），但现阶段仍应定位为强候选而非已验证通用免疫长寿瓶颈。",
"children": [],
"created": "2026-04-25T12:42:21Z",
"updated": "2026-04-25T12:44:14Z"
},
"n105": {
"id": "n105",
"parent": "n82",
"title": "审查 cGAS-STING 是否应被提升为通用免疫/炎症长寿瓶颈",
"rationale": "cGAS-STING 连接 cytosolic DNA 感知、炎症放大与组织退化，且已出现 progeria/longevity 线索，值得单独判定其是否比 IL-1/NLRP3 更接近通用免疫长寿瓶颈。",
"status": "done",
"result": "结论是否定：cGAS-STING 证据虽强，但仍更像 context-dependent 的 inflammaging 放大器而非通用免疫长寿瓶颈；Nature 2023 证明其驱动老化炎症/神经退化，PNAS 2025 在 HGPS 中显示抑制非经典 cGAS-STING 可改善组织衰退并延长寿命，但这类结果仍集中在老化/加速衰老背景与特定组织情境，尚不足以升级为系统级总开关。",
"children": [],
"created": "2026-04-25T12:45:59Z",
"updated": "2026-04-25T12:46:39Z"
},
"n106": {
"id": "n106",
"parent": "n82",
"title": "审查 thymic source restoration 是否具备 healthspan/lifespan 级证据",
"rationale": "先把 broad 的免疫/炎症候选筛选收缩成一个可判定的子问题：胸腺源恢复是当前最符合‘补给源恢复 > 外周 QC > niche 维护’排序的免疫入口，但需要单独审查它有没有 healthspan/lifespan 级证据。",
"status": "done",
"result": "审查结果是否定：检到的 thymic rejuvenation 原始研究（FOXN1-reprogrammed fibroblasts、recombinant FOXN1、GH/ghrelin 等）主要只给出 thymic architecture / thymopoiesis / naïve T cells / TCR diversity / peripheral T cell 恢复，未见直接 healthspan 或 lifespan 终点，因此暂不能把胸腺源恢复升级为通用长寿瓶颈。",
"children": [],
"created": "2026-04-25T12:48:00Z",
"updated": "2026-04-25T12:49:45Z"
},
"n107": {
"id": "n107",
"parent": "n82",
"title": "审查 complement/C1q 轴是否只是 inflammaging readout，而非更高杠杆长寿瓶颈",
"rationale": "在已证伪/降级的 thymus、cGAS-STING、NLRP3、IL-11 之后，需要继续挑一个最可能被误判为‘上游瓶颈’的免疫轴来做反证；补体系统常被当作 inflammaging 放大器，值得审查其是否只是 readout/执行层。",
"status": "done",
"result": "完成反证性审查：C1q/complement 轴虽有随年龄升高、激活 Wnt/β-catenin 和局部再生/神经病理效应的强证据，但检索未见直接 healthspan/lifespan 终点，因此目前应降级为 inflammaging 的执行/放大回路而非通用长寿瓶颈。",
"children": [],
"created": "2026-04-25T12:50:56Z",
"updated": "2026-04-25T12:53:19Z"
},
"n108": {
"id": "n108",
"parent": "n82",
"title": "审查 type I interferon / JAK-STAT chronic activation 是否只是 inflammaging readout，而非更高杠杆长寿瓶颈",
"rationale": "在把补体/C1q 降级后，继续向免疫炎症轴下游/上游交界处寻找更可能被误抬高的节点；慢性 I 型干扰素/JAK-STAT 常见于炎症与衰老，但很可能仍是回路读出。",
"status": "done",
"result": "审查完成：type I interferon / JAK-STAT chronic activation 目前应视为 context-dependent inflammaging 放大器，而非已被证明的通用免疫长寿瓶颈；已有短端粒、DNA damage、POLG mutator 和 progeria 情境下的逆转证据，但缺少足够 wild-type healthspan/lifespan 终点。",
"children": [],
"created": "2026-04-25T12:52:39Z",
"updated": "2026-04-25T12:56:54Z"
},
"n109": {
"id": "n109",
"parent": "n82",
"title": "审查 IL-1 / emergency myelopoiesis 是否具备比其他炎症轴更高的长寿杠杆",
"rationale": "IL-1 / emergency myelopoiesis sits directly upstream of aged HSC bias, niche inflammation, and myeloid expansion; if it has better organism-level evidence than the already-rejected nodes, it could be the next most actionable immune bottleneck.",
"status": "done",
"result": "Completed a focused evidence audit: IL-1 is strongly upstream of HSC inflammaging, emergency hematopoiesis, and Tet2+/− clonal hematopoiesis, but the evidence still lacks organism-level lifespan/healthspan benefit, so it does not outrank stronger universal bottleneck candidates.",
"children": [],
"created": "2026-04-25T12:57:41Z",
"updated": "2026-04-25T14:21:37Z"
},
"n110": {
"id": "n110",
"parent": "n82",
"title": "审计 IL-11 是否能在保持修复/骨稳态可接受的前提下升级为 universal bottleneck",
"rationale": "IL-11 已经被审成强候选，但其组织修复/骨稳态代价说明需要一个更高层的通用判据来决定是否能升级为 universal bottleneck；添加这个子问题能把筛选从“找强候选”推进到“审计其可全身化性”。",
"status": "done",
"result": "完成了 IL-11 的组织特异 tradeoff 审计：现有公开原始因果证据支持其作为强长寿候选，但骨稳态与修复功能风险使其暂不能升级为 universal bottleneck。",
"children": [],
"created": "2026-04-25T14:26:02Z",
"updated": "2026-04-25T14:26:11Z"
},
"n111": {
"id": "n111",
"parent": "n82",
"title": "审计 complement 轴是否具备更高杠杆的系统性炎症入口地位",
"rationale": "先从系统性、可逆且与炎症-代谢耦合最强的候选入手，判断它是否比单一路径炎症因子更上游。",
"status": "done",
"result": "Complement axis has credible systemic inflammaging relevance (calorie-restricted humans show complement deactivation; C3 deficiency improves age-related kidney phenotypes), but I found no direct lifespan/whole-body healthspan causal evidence, so it remains a strong candidate rather than a universal bottleneck.",
"children": [],
"created": "2026-04-25T14:29:55Z",
"updated": "2026-04-25T14:30:25Z"
},
"n112": {
"id": "n112",
"parent": "n82",
"title": "审计 NLRP3 炎症小体是否能升级为长寿瓶颈",
"rationale": "NLRP3 是经典炎症小体节点，若有原始因果的寿命/健康寿命支持，可作为与 complement 并行的高优先候选。",
"status": "done",
"result": "完成反证审计：NLRP3 具备小鼠层面的 lifespan/healthspan 正例（PMID 31625260、31975052、37487005、39192596），但证据主要局限于特定性别/组织/病理背景或组合干预，仍不足以升级为通用长寿瓶颈。",
"children": [],
"created": "2026-04-25T14:29:55Z",
"updated": "2026-04-25T14:34:01Z"
},
"n113": {
"id": "n113",
"parent": "n82",
"title": "审计 cGAS-STING 是否是更上游的炎症-衰老放大器",
"rationale": "cGAS-STING 连接 DNA 损伤、线粒体泄漏与先天免疫，可能是更上游的衰老放大器，需要单独验证。",
"status": "done",
"result": "完成审计：cGAS-STING 确实是更上游的炎症-衰老放大器，且已有 PNAS 2025 原始研究显示其参与 cellular/organismal aging；但目前证据仍以机制与健康表型为主，缺少直接寿命终点，而且 STING/cGAS 缺失会带来脂质与胆固醇稳态代价，因此暂不能升级为 universal longevity bottleneck。",
"children": [],
"created": "2026-04-25T14:29:55Z",
"updated": "2026-04-25T14:38:14Z"
},
"n114": {
"id": "n114",
"parent": "n82",
"title": "把 TNF / IL-6 作为低优先级对照轴排除",
"rationale": "TNF / IL-6 类经典炎症因子往往更像读出或局部放大器，适合作为对照来排除伪上游。",
"status": "done",
"result": "用 PMID 33260150 证明 TNFα blockade 可改善 aging mouse 的肌少症并延长生存，但证据仍属组织/病理回路特异，不能升级为 universal longevity bottleneck；IL-6 检索未见同等直接延寿证据，因此作为低优先级对照轴被排除。",
"children": [],
"created": "2026-04-25T14:29:55Z",
"updated": "2026-04-25T14:41:25Z"
},
"n115": {
"id": "n115",
"parent": "n82",
"title": "把 TNF / IL-6 作为低优先级对照轴排除",
"rationale": "在 cGAS-STING 之后，需要一个明确的低优先级对照轴，用来避免把“炎症强相关”误判成“更上游、更值得优先”的长寿瓶颈；TNF/IL-6 是最典型的对照。",
"status": "done",
"result": "已将 TNF/IL-6 定为低优先级对照轴：TNF 有组织特异的 aging mouse 生存/肌少症改善信号，但不构成全身统一瓶颈；对 IL-6 的直接寿命检索未找到同等明确的原始证据，因此二者都不应升级为默认长寿主靶点。",
"children": [],
"created": "2026-04-25T14:38:21Z",
"updated": "2026-04-25T14:53:49Z"
},
"n116": {
"id": "n116",
"parent": "n82",
"title": "审计 type I interferon / JAK-STAT 是否是更高杠杆的免疫-衰老入口",
"rationale": "Type I interferon sits very upstream in nucleic-acid sensing and can couple innate inflammation to HSC exhaustion and stem-cell dysfunction; if it has lifespan/healthspan evidence, it may outrank more local inflammatory mediators.",
"status": "done",
"result": "审计结论：type I interferon / JAK-STAT 仍应视为强烈的、情境依赖的 inflammaging 放大器，而不是已被验证的通用长寿瓶颈；PubMed 未检到 IFNAR/lifespan 直接证据，且公开血液系统研究显示 basal IFN-I 对 neonatal/juvenile hematopoiesis 仅有 modest effects（PMID 36724510），更支持‘上游参与者’而非‘总开关’。",
"children": [],
"created": "2026-04-25T14:43:04Z",
"updated": "2026-04-25T14:52:09Z"
},
"n117": {
"id": "n117",
"parent": "n82",
"title": "审计 complement cascade 是否能升级为长寿瓶颈",
"rationale": "Complement can act as a systemic innate amplifier and may bridge tissue damage, senescence, and immune dysfunction; it is a plausible non-canonical bottleneck candidate.",
"status": "done",
"result": "审计完成：补体级联可视为全身性 inflammaging 放大器候选，但仅检到 calorie-restricted humans 的 complement deactivation 线索与若干病理/机制关联，未找到直接支持 whole-body healthspan/lifespan 的原始因果证据，因此不应升级为 universal longevity bottleneck。",
"children": [],
"created": "2026-04-25T14:43:04Z",
"updated": "2026-04-25T14:55:37Z"
},
"n118": {
"id": "n118",
"parent": "n82",
"title": "审计 IL-1 / MyD88 轴是否比 TNF/IL-6 更值得优先",
"rationale": "IL-1 / MyD88 is a canonical inflammaging axis with some upstreamity over IL-6/TNF; test whether it offers stronger causal breadth than the already-downgraded cytokines.",
"status": "done",
"result": "Completed audit: IL-1/MyD88 ranks above TNF/IL-6 as a more upstream inflammaging loop (HSC bias, microbiome-driven inflammaging, emergency myelopoiesis, Tet2+/− CH), but available public evidence still stops short of organism-level lifespan or broad multi-organ healthspan validation.",
"children": [],
"created": "2026-04-25T14:43:04Z",
"updated": "2026-04-25T14:58:51Z"
},
"n119": {
"id": "n119",
"parent": "n82",
"title": "审计适应性免疫衰退（胸腺/naive repertoire）是否是源头级瓶颈",
"rationale": "Adaptive immune collapse (thymic involution, clonal skewing, loss of naive repertoire) may be a source-level bottleneck rather than a downstream readout; if reversible, it could be a true system-level lever.",
"status": "done",
"result": "审计结论：适应性免疫衰退中的 thymic involution 是可逆的上游免疫入口，能恢复 naive T-cell 输出与功能免疫读出；但现阶段仍缺少寿命/健康寿命层面的直接证据，因此它应被视为高优先级免疫瓶颈候选，而非已验证的全身性长寿源头级瓶颈。",
"children": [],
"created": "2026-04-25T14:43:04Z",
"updated": "2026-04-25T14:59:59Z"
},
"n120": {
"id": "n120",
"parent": "n82",
"title": "审计 complement cascade 是否能升级为长寿瓶颈",
"rationale": "既然 IFN-I/JAK-STAT 只能算强候选但未升级为通用瓶颈，需要继续用其它更上游或更具组织广谱性的免疫轴作对照，避免在局部正例上过度外推。",
"status": "done",
"result": "审计完成：补体级联虽有更强系统性相关与单器官健康寿命改善信号（如 C3 lowering 改善老龄鼠海马功能、CR humans 的 complement deactivation），但仍缺少 organism-level lifespan / multi-organ healthspan 的原始因果证据，不能升级为通用长寿瓶颈。",
"children": [],
"created": "2026-04-25T14:52:16Z",
"updated": "2026-04-25T15:01:53Z"
},
"n121": {
"id": "n121",
"parent": "n82",
"title": "审计 IL-11 是否应升格为免疫/炎症轴中的当前第一候选",
"rationale": "IL-11 已有直接鼠类寿命/健康寿命证据，可能把免疫/炎症筛选从‘上游候选’推进到‘当前第一优先级’；需要单独审计其与 IL-1/MyD88、thymic involution 等候选的相对位置。",
"status": "pending",
"result": "",
"children": [],
"created": "2026-04-25T15:03:21Z",
"updated": "2026-04-25T15:03:21Z"
},
"n122": {
"id": "n122",
"parent": "root",
"title": "审计 IL-11 的寿命获益是否主要来自免疫/炎症重编程",
"rationale": "把 IL-11 的寿命获益拆成可审计的机制归因：先区分免疫/炎症重编程与骨代谢等系统副作用，才能判断它是通用长寿瓶颈还是组织代价交换。",
"status": "done",
"result": "完成 IL-11 机制归因审计：当前证据支持将其寿命获益拆分为免疫/炎症重编程、骨代谢副作用与修复/再生 pleiotropy 三个独立审查维度，尚不能单归因为免疫/炎症重编程。",
"children": [],
"created": "2026-04-25T15:05:05Z",
"updated": "2026-04-25T15:06:13Z"
},
"n123": {
"id": "n123",
"parent": "root",
"title": "检索并拆分 IL-11 的成人哺乳动物原始因果证据：免疫/炎症获益 vs 骨代谢与创伤修复代价",
"rationale": "当前主线需要从‘IL-11 机制归因审计’推进到‘成人哺乳动物原始因果证据’层面，直接判断其免疫/炎症获益与骨代谢、创伤修复代价是否可分离。",
"status": "done",
"result": "已把成人哺乳动物 IL-11 原始因果证据拆成两块：骨稳态代价有直接证据（PMID 36424386 / PMCID PMC9691688），而骨折愈合与皮肤创伤修复的直接因果证据截至当前仍未检出；因此 IL-11 的‘免疫/炎症获益’与‘骨/修复代价’不能混为一谈。",
"children": [],
"created": "2026-04-25T15:08:08Z",
"updated": "2026-04-25T15:14:43Z"
},
"n124": {
"id": "n124",
"parent": "root",
"title": "审计 IL-11 的修复代价是否存在直接成人哺乳动物原始反例",
"rationale": "当前 IL-11 候选最脆弱的点是系统性 pleiotropy：若其抑寿/促寿信号伴随修复代价，则不能升级为通用长寿瓶颈。先找成人哺乳动物原始研究中对骨折/创伤修复的直接反例，能最快证伪过度乐观解释。",
"status": "done",
"result": "完成定向检索：未检出成人哺乳动物中以 IL-11 抑制/缺失为核心、且直接测量骨折愈合或皮肤创伤修复的原始因果反例；相邻命中主要是 gp130/黏膜修复/炎症纤维化，不足以外推为目标终点。",
"children": [],
"created": "2026-04-25T15:15:49Z",
"updated": "2026-04-25T15:17:31Z"
},
"n125": {
"id": "n125",
"parent": "root",
"title": "审计 IL-11 抑制在成年哺乳动物中对多器官纤维化与寿命/健康寿命的直接因果证据",
"rationale": "把当前综合焦点收束到可检验的 IL-11 证据地图，直接判断它是否同时影响衰老相关多器官纤维化与健康寿命/寿命。",
"status": "done",
"result": "完成证据审计：IL-11 抑制在成年/老年小鼠中已有直接 healthspan/lifespan 原始证据（Nature 2024 PMID 39020175），并且在 Alport 肾病模型中有延寿原始证据（PMID 35140116）；但器官特异纤维化效应并不一致，MASH 肝纤维化模型中被描述为 limited roles（PMID 39536410）。",
"children": [],
"created": "2026-04-25T15:18:23Z",
"updated": "2026-04-25T15:20:35Z"
},
"n126": {
"id": "n126",
"parent": "root",
"title": "量化 IL-11 抑制在成年/老年小鼠中的寿命与健康寿命效应大小",
"rationale": "IL-11 已有成人哺乳动物 healthspan/lifespan 原始证据，下一步需要量化效应大小、年龄窗口与干预代价，判断它到底是‘可用杠杆’还是‘机制噪声’。",
"status": "done",
"result": "已量化到公开原始证据中的效应大小：成年/老年小鼠连续抑制 IL-11 可使中位寿命在雄鼠延长 22.5%、雌鼠延长 25%，并伴随多项 healthspan/pathology 改善；同时保留单研究支撑与跨背景复现不足的边界。",
"children": [],
"created": "2026-04-25T15:21:55Z",
"updated": "2026-04-25T15:23:39Z"
},
"n127": {
"id": "n127",
"parent": "root",
"title": "筛选蛋白稳态/自噬/线粒体中的第三个高杠杆长寿瓶颈候选",
"rationale": "IL-11/炎症线索已推进到寿命终点，下一步应并行验证是否还存在能同时触达健康寿命与广谱组织稳态的第三类上游瓶颈；蛋白稳态/自噬是典型候选。",
"status": "done",
"result": "已从蛋白稳态/自噬/线粒体轴中筛出 autophagy 作为第三个高杠杆长寿瓶颈候选：Atg5 过表达小鼠存在直接寿命正例，而蛋白酶体、热休克/分子伴侣与 ER stress/UPR 轴此前已被审计为未达基线正例。",
"children": [
"n128",
"n129",
"n130",
"n131",
"n132",
"n133"
],
"created": "2026-04-25T15:24:51Z",
"updated": "2026-04-25T15:52:06Z"
},
"n128": {
"id": "n128",
"parent": "n127",
"title": "审计 mTOR/rapamycin 是否已具备直接寿命终点证据并可作为基线候选",
"rationale": "先验证是否存在已经跨过寿命终点门槛的具体节点，避免把泛化自噬/线粒体概念误判为候选。",
"status": "done",
"result": "已确认 rapamycin/mTOR 具备直接成年哺乳动物寿命终点：PMID 19587680 报告晚期喂食 rapamycin 延长遗传异质小鼠寿命，因此它可作为自噬/线粒体筛选的基线正例，而不是把过程名自动升格。",
"children": [],
"created": "2026-04-25T15:31:43Z",
"updated": "2026-04-25T15:32:31Z"
},
"n129": {
"id": "n129",
"parent": "n127",
"title": "审计自噬增强是否具有与 mTOR 相当的直接寿命终点证据",
"rationale": "如果自噬是独立候选，必须能拿出干预 + 寿命/健康寿命终点，而不是仅有机制与通路相关性。",
"status": "done",
"result": "完成审计：未找到“自噬增强”本身具有与 mTOR/rapamycin 相当的成人哺乳动物直接寿命终点证据；现有命中主要是机制/中介性证据（如 spermidine 促进自噬并在模型生物中促寿、fasting-mediated autophagy 与 longevity 相关），但缺少像 rapamycin 那样的明确成年哺乳动物 organism-level 延寿原始研究。",
"children": [],
"created": "2026-04-25T15:31:43Z",
"updated": "2026-04-25T15:35:54Z"
},
"n130": {
"id": "n130",
"parent": "n127",
"title": "审计线粒体干预是否具有与 mTOR 相当的直接寿命终点证据",
"rationale": "如果线粒体是独立候选，也必须证明有可操纵节点能触达 organism-level 终点，而不是只停留在代谢或细胞功能改善。",
"status": "done",
"result": "定位到线粒体靶向抗氧化干预的直接寿命终点正例：SkQ1（PMID 22166671, 28209927）与 MitoQ（PMID 31521745），说明线粒体并非纯机制候选，但证据高度异质、远不如 rapamycin 统一。",
"children": [],
"created": "2026-04-25T15:31:43Z",
"updated": "2026-04-25T15:38:12Z"
},
"n131": {
"id": "n131",
"parent": "n127",
"title": "审计蛋白酶体增强是否具有直接寿命终点证据",
"rationale": "蛋白稳态候选里，蛋白酶体增强是最接近‘可干预节点’而非纯过程名的分支；先审计它是否已有成年哺乳动物寿命终点，能快速判断该轴能否升格。",
"status": "done",
"result": "完成审计：未检出成年/老年哺乳动物中“蛋白酶体增强”作为广义干预的直接寿命终点正例；现有命中主要是疾病模型中的蛋白稳态/病理改善（如 APP、TDP-43 等），不足以把蛋白酶体轴升格为当前与 rapamycin 同级的基线长寿候选。",
"children": [],
"created": "2026-04-25T15:39:56Z",
"updated": "2026-04-25T15:40:45Z"
},
"n132": {
"id": "n132",
"parent": "n127",
"title": "审计热休克/分子伴侣增强是否具有直接寿命终点证据",
"rationale": "热休克/分子伴侣轴常被归入蛋白稳态，但需要单独审计其是否存在 organism-level lifespan/healthspan 证据，避免把细胞保护表型误判为长寿瓶颈。",
"status": "done",
"result": "完成审计：未找到成年/老年哺乳动物中单纯增强热休克/分子伴侣并以寿命终点为主读出的明确正例；非哺乳动物存在多条正例，但鼠中也有HSP70过表达早死负例，故该轴暂不升级为baseline-positive长寿节点。",
"children": [],
"created": "2026-04-25T15:39:56Z",
"updated": "2026-04-25T15:43:22Z"
},
"n133": {
"id": "n133",
"parent": "n127",
"title": "审计 ER stress / UPR 调控是否具有直接寿命终点证据",
"rationale": "ER stress / UPR 也是蛋白稳态的重要分支，若存在直接寿命终点的具体干预节点，可作为与 mTOR/IL-11 并列的第三类高杠杆候选。",
"status": "done",
"result": "Completed audit: no clear adult/aged mammalian study was found that targets ER stress/UPR and uses direct lifespan or healthspan as the primary endpoint; retrieved hits were mostly pathology/metabolic readouts, while longevity positives were in C. elegans.",
"children": [],
"created": "2026-04-25T15:39:56Z",
"updated": "2026-04-25T15:46:54Z"
},
"n134": {
"id": "n134",
"parent": "root",
"title": "核查成年哺乳动物中自噬增强是否已有直接寿命/健康寿命正例",
"rationale": "把‘自噬增强是否有成人哺乳动物寿命正例’从泛化过程问题收敛为单一可证伪子命题，避免继续在机制热度里漂移。",
"status": "done",
"result": "已确认成年哺乳动物中存在自噬增强的直接寿命正例：Atg5 过表达小鼠（PMID 23939249）延长寿命，可作为自噬轴的基线正例。",
"children": [
"n136"
],
"created": "2026-04-25T16:09:20Z",
"updated": "2026-04-25T16:16:09Z"
},
"n135": {
"id": "n135",
"parent": "root",
"title": "核查成年哺乳动物中是否存在第二条自噬寿命/健康寿命原始正例",
"rationale": "继续沿自噬轴做最窄问题：先判定 Atg5 之外是否还有第二条成年哺乳动物寿命/健康寿命原始正例，避免把单一正例误判成可泛化瓶颈。",
"status": "failed",
"result": "针对成年哺乳动物自噬轴的第二条原始寿命/健康寿命正例，已用 PubMed 定向检索 Atg5/Atg7/Beclin1/TFEB 与 lifespan/healthspan 组合，未检出可确认的第二条成年哺乳动物原始正例；目前只稳定保留 Atg5 过表达这一条正例。",
"children": [
"n138"
],
"created": "2026-04-25T16:11:09Z",
"updated": "2026-04-25T16:30:37Z"
},
"n136": {
"id": "n136",
"parent": "n134",
"title": "系统扫描成年哺乳动物中以自噬增强为机制的寿命/健康寿命原始正例",
"rationale": "n135 的定向检索未找到第二条原始正例，需要扩大到所有“以自噬增强为机制”的成年哺乳动物寿命/健康寿命研究，避免仅在少数效应子上做过窄结论。",
"status": "done",
"result": "完成成年哺乳动物自噬增强原始正例的系统扫描：除 Atg5 过表达这一已知正例外，围绕 TFEB、Beclin1、广义 autophagy enhancement、spermidine 等具体干预/终点组合未再检出可确认的第二条成年哺乳动物寿命/健康寿命原始正例，因此当前结论仍应维持为 baseline-positive，而非普适类效应。",
"children": [
"n137"
],
"created": "2026-04-25T16:16:09Z",
"updated": "2026-04-25T16:28:32Z"
},
"n137": {
"id": "n137",
"parent": "n136",
"title": "判定 Htt polyQ deletion 是否应计入自噬增强正例",
"rationale": "PubMed 检索暴露出一个边界命中：Htt polyQ stretch deletion 被描述为增强神经元自噬并延长寿命，但它可能不是直接的自噬增强干预。需要单独审查，防止把边界/间接证据误算成第二条正例。",
"status": "done",
"result": "已判定 PMID 20140187 不能算作第二条‘直接自噬增强’正例：它是 huntingtin polyQ stretch deletion 的间接遗传背景改变，虽然文中报告增强 neuronal autophagy 并延长小鼠寿命，但不满足当前审计要求的‘明确自噬增强干预 + 成年哺乳动物寿命/健康寿命终点’双约束。",
"children": [],
"created": "2026-04-25T16:22:13Z",
"updated": "2026-04-25T16:23:14Z"
},
"n138": {
"id": "n138",
"parent": "n135",
"title": "逐一核查已知自噬诱导剂/自噬上调干预是否存在成年哺乳动物寿命/健康寿命原始正例",
"rationale": "当前 n135 失败的原因是未找到第二条原始正例；下一步应把‘自噬增强’拆成可直接检验的具体干预候选，逐一核对是否真的带来成年哺乳动物寿命/健康寿命终点。",
"status": "failed",
"result": "对已知自噬上调/诱导干预（rapamycin、spermidine、trehalose、general autophagy induction）逐项定向检索后，未能确认第二条成年哺乳动物原始寿命/健康寿命正例；命中的多为机制、疾病模型或与寿命终点不相关的研究，因此该子问题目前失败而非成立。",
"children": [],
"created": "2026-04-25T16:30:37Z",
"updated": "2026-04-25T16:31:53Z"
},
"n139": {
"id": "n139",
"parent": "root",
"title": "横向搜寻第二条成年哺乳动物自噬增强原始正例",
"rationale": "在已确认 Atg5 过表达这一条直接正例后，需要继续横向扫描其他独立的自噬增强干预，避免单例升级过度；把搜索拆成具体候选集合更利于排除机制替代终点。",
"status": "done",
"result": "找到第二条成年哺乳动物自噬增强原始正例：PMID 39164234 报告药理增强 TFEB-mediated autophagy 的 CXM102 在中年雄鼠中改善骨丢失并在摘要中明确给出 lifespan 延长。",
"children": [],
"created": "2026-04-25T16:33:21Z",
"updated": "2026-04-25T16:34:44Z"
},
"n140": {
"id": "n140",
"parent": "root",
"title": "横向检索第三条成年哺乳动物自噬增强原始正例",
"rationale": "当前 TFEB/Atg5 正例已经占住了证据位，需要再找一条独立于它们的成年哺乳动物自噬增强原始正例，才能判断 autophagy 轴是否有多个 organism-level positive hits。",
"status": "failed",
"result": "PubMed 定向检索未检出可确认的第三条成年哺乳动物自噬增强原始正例：宽泛 query 与 rapamycin/spermidine/beclin1/TFEB 组合都没有给出满足“干预明确增强自噬 + 成年哺乳动物 + lifespan/healthspan 原始终点”的独立正例；命中的近邻证据要么是机制/疾病模型，要么不是自噬增强（如 chloroquine 属自噬抑制）或终点不合格。",
"children": [],
"created": "2026-04-25T16:35:24Z",
"updated": "2026-04-25T16:37:14Z"
},
"n141": {
"id": "n141",
"parent": "root",
"title": "审计是否存在被遗漏的第三条成年哺乳动物自噬增强正例",
"rationale": "作为严厉审稿式反证分支，继续检查是否存在被前序检索漏掉的第三条成年哺乳动物自噬增强原始正例；若不存在，可更稳固地把当前证据地图降级为‘至多两条’。",
"status": "done",
"result": "PubMed 宽泛与节点级检索未找到可确认的第三条成年哺乳动物自噬增强原始寿命/健康寿命正例；当前证据边界仍停留在 baseline-positive 而非三条独立正例支持。",
"children": [],
"created": "2026-04-25T16:38:10Z",
"updated": "2026-04-25T16:39:17Z"
},
"n142": {
"id": "n142",
"parent": "root",
"title": "把 senolytic→OSK 顺序实验的阴性检索转成最小证据门槛",
"rationale": "当前多组织、多体系检索都未找到 senolytic→OSK/partial reprogramming 的原始顺序实验；需要把这一空白沉淀成可复用的检索/判定协议，避免未来把阴性检索误读为充分反证。",
"status": "done",
"result": "将 senolytic→OSK 顺序实验的阴性检索沉淀为最小证据门槛：同体系、明确 senolytic 预处理、明确 OSK/OSKM、可比较终点；PubMed 组合检索未返回可用原始条目，当前结论仍是证据缺席而非已完成反证。",
"children": [],
"created": "2026-04-25T16:41:23Z",
"updated": "2026-04-25T16:41:39Z"
},
"n143": {
"id": "n143",
"parent": "root",
"title": "横向核验骨组织中 OSK vs senolytic 是否存在直接 head-to-head 原始证据",
"rationale": "皮肤之外，骨组织同时出现了 OSK 与 senolytic 的各自原始正例，值得单独核验是否存在同组织同终点直接比较，以避免只靠并列正例下结论。",
"status": "failed",
"result": "PubMed 定向检索骨/软骨/骨关节炎中 OSK/partial reprogramming 与 navitoclax/ABT-263 的原始 head-to-head 设计均为 0 命中；目前只能确认比较证据缺失，不能确认存在直接对照。",
"children": [],
"created": "2026-04-25T16:43:14Z",
"updated": "2026-04-25T16:43:44Z"
},
"n144": {
"id": "n144",
"parent": "root",
"title": "在骨组织中构造 OSK vs senolytic 的最小可比代理证据",
"rationale": "直接 head-to-head 仍找不到时，需要把探索升级为比较证据缺失下的最小代理判据，避免无限追着同类空搜。",
"status": "done",
"result": "已将骨组织中的探索降级为比较证据缺失，并转入最小可比代理证据构造；同时沉淀了“无 head-to-head 就不要做路线优劣结论”的骨组织特化边界。",
"children": [],
"created": "2026-04-25T16:45:14Z",
"updated": "2026-04-25T16:45:30Z"
},
"n145": {
"id": "n145",
"parent": "root",
"title": "在骨组织里定义 OSK 与 senolytic 可对齐的最小代理终点",
"rationale": "当前骨组织里已确认缺少 OSK vs senolytic 的直接 head-to-head；下一步应把“比较证据缺失”转成最小可比代理终点的可执行方案，以便判断后续实验/检索是否能对齐同研究、同组织、同读出。",
"status": "done",
"result": "定义了骨组织中 OSK 与 senolytic 可对齐的最小代理终点分层：年龄/重juvenation、组织功能、安全/身份三层，并将其锚定到比较证据缺失边界与肌骨 aging clock 文献。",
"children": [],
"created": "2026-04-25T16:46:19Z",
"updated": "2026-04-25T16:47:59Z"
},
"n146": {
"id": "n146",
"parent": "root",
"title": "审计骨-软骨-椎间盘邻近系统是否存在可替代的 OSK vs senolytic 头对头证据",
"rationale": "把“骨组织无直接 head-to-head”这一失败结论推进到更严格的邻近系统审计：如果骨/软骨/椎间盘等相邻系统也只有各自正例而无统一读出，就能进一步证伪用近邻系统替代 head-to-head 的想法。",
"status": "done",
"result": "PubMed 定向检索骨-软骨-椎间盘邻近系统的 OSK/partial reprogramming vs senolytic 组合未检出任何 head-to-head 原始研究；证据缺口从骨组织扩展到近邻骨关节系统。",
"children": [],
"created": "2026-04-25T16:50:39Z",
"updated": "2026-04-25T16:50:58Z"
},
"n147": {
"id": "n147",
"parent": "root",
"title": "把已审计的组织证据整合成 OSK vs senolytic 跨组织比较证据缺口地图",
"rationale": "前面已在皮肤、骨与邻近系统证伪/降级了局部 head-to-head 证据；需要把这些散点整合成一张跨组织证据缺口地图，才能判断下一步是继续横向搜寻还是转向最小可比代理。",
"status": "done",
"result": "并行检索 PubMed/网页未检出 OSK vs senolytic 在骨、皮肤、软骨、椎间盘等候选组织中的直接 head-to-head 原始证据，已将其整合为跨组织比较证据缺口地图。",
"children": [],
"created": "2026-04-25T16:51:41Z",
"updated": "2026-04-25T16:52:32Z"
},
"n148": {
"id": "n148",
"parent": "root",
"title": "审计 senolytic→OSK 顺序联合是否有原始证据",
"rationale": "顺序联合可能比单药对单药更有信息量；先确认是否存在 senolytic 预处理后再做 OSK/partial reprogramming 的原始证据，能直接决定下一步是找证据还是转向设计缺口分析。",
"status": "done",
"result": "完成顺序联合审计：PubMed 定向检索与检索词变体均未检出同一原始研究内的 senolytic 预处理→OSK/partial reprogramming 证据，结论降级为证据缺席而非路线无效。",
"children": [],
"created": "2026-04-25T16:53:27Z",
"updated": "2026-04-25T16:55:12Z"
},
"n149": {
"id": "n149",
"parent": "root",
"title": "寻找 senolysis 与 partial reprogramming 的非顺序耦合机制",
"rationale": "直接的 senolytic→OSK 顺序原始实验已被反复审计为空；下一步更高信息量的切口是寻找二者是否存在非顺序耦合机制（共享应激阈值、时序窗口、细胞类型依赖），从机制层面判断它们是相互增益还是互相冲突。",
"status": "done",
"result": "确认了一个跨场景可复用的机制判断：senescence/SASP 既可能是重编程负担，也可能在特定阶段充当促再生生态位，因此 senolysis 与 partial reprogramming 的关系应按组织/阶段/读出拆分，而不能默认前置清障必然增益。",
"children": [],
"created": "2026-04-25T16:56:29Z",
"updated": "2026-04-25T16:57:17Z"
},
"n150": {
"id": "n150",
"parent": "root",
"title": "在单一组织中建立 senescence 负担 vs 生态位的可证伪判别条件",
"rationale": "把当前主线从“是否有证据”推进到“在单一组织中如何可证伪地区分 senescence 是负担还是生态位”，这是下一步最小可验证方案的核心切入点。",
"status": "done",
"result": "完成了单一组织内 senescence 负担态/生态位态的可证伪判别框架，并用 context-dependent wound healing 作为可迁移证据锚点；PubMed 检到 2025 年综述 PMID 40318767 支持该框架。",
"children": [],
"created": "2026-04-25T16:58:06Z",
"updated": "2026-04-25T16:59:06Z"
},
"n151": {
"id": "n151",
"parent": "root",
"title": "检索急性修复中 senolytic 是否会加重伤口愈合失败",
"rationale": "如果急性修复/再生里清除 senescent cells 会直接损害组织修复，那么“senescence 可作为 pro-regenerative niche”这条关键支撑就会被削弱；这是当前 OSK+senolytic 组合最可能失败的地方，值得优先证伪。",
"status": "done",
"result": "PubMed 未检出直接的‘senolytic 预处理导致急性修复更差’原始干预研究，但抓到 fracture healing 的时空 SASP atlas，明确提示 senescence/SASP 存在阶段性 therapeutic window；因此‘先清除衰老细胞一定更好’在修复场景下仍是高风险假设。",
"children": [],
"created": "2026-04-25T17:00:02Z",
"updated": "2026-04-25T17:02:01Z"
},
"n152": {
"id": "n152",
"parent": "root",
"title": "检索急性修复中直接 senolytic 干预是否延迟或恶化愈合",
"rationale": "上一轮只拿到 stage-dependent SASP atlas，尚未找到直接 senolytic 干预会不会拖慢/恶化急性修复的原始因果证据；补这一刀才能真正证伪‘senolysis 总是安全增益’。",
"status": "done",
"result": "完成定向空检索：在 PubMed 中找到皮肤糖尿病创面（PMID 39310100）和老年骨折修复（PMID 35426369、35426372）的原始研究，结果均指向 senolytic/衰老清除促进而非延迟愈合，因此‘senolytic 会延迟或恶化急性修复’不能作为默认泛化命题。",
"children": [],
"created": "2026-04-25T17:02:01Z",
"updated": "2026-04-25T17:04:17Z"
}
}
}